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Risk of Newly-diagnosed Depression, Treatment and its Economic Outcomes among 
Elderly Medicare Beneficiaries with Incident Breast, Colorectal or Prostate Cancer 
Monira Mansour Alwhaibi 
 
Depression is a highly prevalent chronic condition among the elderly cancer survivors. It is 
estimated that 5-25% of elderly cancer survivors suffer from depression. Depression co-existing 
with cancer is associated with many negative health consequences such as high mortality, poor 
health related quality of life and high healthcare utilization and expenditures. However, 
depression is treatable with pharmacotherapy, psychotherapy or combination of both. There are 
no studies that examine the variations in the risk of depression by cancer types and there are few 
studies that examined the rates of depression treatment among elderly with cancer. In addition, 
there is lack of evidence on the impact of depression treatment on the economic outcomes of 
cancer survivors. To fill the knowledge gap, the three related aims of this dissertation were to: 
(1) examine the variations in the risk of depression by cancer types among elderly with incident 
breast, colorectal, and prostate cancer; (2) identify the rates of depression treatment and the 
factors associated with depression treatment among elderly with newly-diagnosed depression and 
incident breast, colorectal and prostate cancer; (3) analyze the impact of depression treatment on 
the healthcare expenditures among elderly with newly-diagnosed depression and incident breast, 
colorectal and prostate cancer. The study used a retrospective cohort study design, using multiple 
years (2002-2011) of the cancer registry data from the Surveillance, Epidemiology and End 
Results (SEER) program linked with the Medicare claims data, the American community survey 
census-tract files and the Area Health Resource Files.  In the first aim, among elderly with 
incident breast, colorectal and prostate cancer (N= 53,821), women with colorectal cancer had 
28.0% higher risk of newly-diagnosed depression as compared to women with breast cancer; 
men with colorectal cancer had 104.0% higher risk of newly-diagnosed depression as compared 
to men with prostate cancer. Elderly diagnosed with cancer at an advanced stage had a 61.0% 
higher risk of newly-diagnosed depression as compared to those diagnosed with cancer at an 
early stage. Elderly with higher number of primary care providers visits had a higher newly-
diagnosed depression as compared to those with lower number of primary care providers visits. 
In the second aim, among elderly with newly-diagnosed depression and incident breast, 
colorectal and prostate cancer (N= 1,673), 45.7% received antidepressants only; 8.8% received 
psychotherapy only; 18.4% received combined therapy; and 27.1% received no treatment for 
depression. Elderly cancer survivors who received ongoing cancer treatment were less likely to 
receive psychotherapy only, or combination therapy. Elderly living in counties with a higher 
percentage of psychologists were more likely to receive psychotherapy only, or combination 
therapy. In the third aim, among elderly with newly-diagnosed depression and incident breast, 
colorectal and prostate cancer (N= 1,502), the average 1-year total healthcare expenditures after 
depression diagnosis were higher among those who received depression treatment as compared 
to no depression treatment. The associations between depression treatment and the higher 
healthcare expenditures were observed across all types of healthcare expenditures (inpatient, 
outpatient, prescription drugs, and other expenditures). To summarize, this dissertation found 
that there are variations in the risk of newly-diagnosed depression by cancer type. Among cancer 





form of depression treatment; cancer-related factors were associated with depression treatment; 
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Chapter 1  
Introduction  
 
1.1 Background  
 
It is projected that there will be 19 million cancer survivors in the United States (US) by 
2024. “A cancer survivor is a person who has been diagnosed with cancer, from the time of 
diagnosis throughout his or her life.” (1). Cancer is the disease of the elderly; 63% of cancer 
survivors are age 65 years and older (2). Cancer survivors often find the diagnosis of cancer to be 
a very stressful life event; they may face a fear of death, changes in physical health, life plans, 
work, and social roles and may face some financial concerns (3). As a result, some cancer 
survivors may have difficulties adjusting to the diagnosis of cancer and may develop 
psychological side effects. Evidence from the literature suggests the psychological effects of a 
cancer diagnosis may range from sadness to depressive symptoms to clinical depression, 
hereinafter referred to as “depression” (4). 
1.1.1 Depression Diagnosis   
According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-V), a depression diagnosis is confirmed if individuals present with at least five symptoms 
which persist over a period of at least two weeks (5). These symptoms include: 1) depressed 
mood; 2) loss of interest or pleasure in usual activities (anhedonia); 3) weight loss or change in 
appetite; 4) change in sleep (insomnia or hypersomnia); 5) change in activity; 6) fatigue/loss of 
energy; 7) feelings of guilt/worthlessness; 8) difficulty  concentrating or thinking; 9) thoughts of 
death or suicide. Depression is present when these symptoms cause clinically significant distress 
and impairment in social, occupational or other important areas of functioning (5). 
There are different tools to diagnose depression; the gold standard for depression 





providers that is based on the symptom criteria for a major depressive disorder in the DSM-IV 
(5). However, because the structured clinical interview can be time-consuming and expensive to 
administer, epidemiological studies often use depression rating scales with cut-off points to 
diagnose depression. Depression rating scales can be administered by trained interviewers or can 
be completed by patients (a patient self-report scale). Examples of the scales administered by 
trained interviewers include the Hamilton Depression Rating Scale (HDRS) and the 
Montgomery-Åsberg Depression Rating Scale. Examples of patient self-report scales include the 
Beck Depression Inventory, the Center for Epidemiologic Studies Depression Scale, the Hospital 
Anxiety and Depression Scale (HADS), the Geriatric Depression Scale, the Patient Health 
Questionnaire, and the Zung Self-rating Depression Scale. These scales are usually used in 
Randomized Control Trials (RCTs) as screening tools to identify depression before conducting a 
structured clinical interview or as assessment tools for response to depression treatment. 
1.1.2 Prevalence of Depression among Cancer Survivors 
Using these self-reported scales or physician diagnoses, it has been found that prevalence 
rates of depression are higher among cancer survivors as compared to their matched non-cancer 
controls (6-8). It is estimated that 10-25% of breast cancer survivors (7,9,10), 8-18% of 
colorectal survivors (11,12), and 5-10% of prostate cancer survivors suffer from depression 
(13,14). The variability in the prevalence rates of depression within any cancer types is due to 
heterogeneous samples, different settings, time periods, and the use of different instruments used 
to diagnose depression. Some studies used the structured clinical interview (9) or the 
International Classifications of Diseases – 9th edition, Clinical Modification Codes (ICD-9-CM) 
diagnostic codes recorded in healthcare claims (11-14). Other studies used self-reported 
symptoms scales with cut-off points to diagnose clinical depression, specifically the Hospital 





1.1.3 Incidence of Depression among Cancer Survivors 
While the prevalence of depression among cancer patients is examined extensively in the 
literature, studies on the incidence of depression after cancer diagnosis are sparse. Studies that 
examined the incidence rate of depression have compared the rate of depression among cancer 
survivors to matched non-cancer cohorts (6-8). An observational study using the Surveillance 
Epidemiology and End Results (SEER)-Medicare database for the years 1998-2002 examined 
the age-race adjusted incidence rate of depression among 51,590 elderly Medicare beneficiaries 
(age ≥ 66) with breast cancer (7). This study found a 12-month depression incidence rate was 24 
per 1000 person-years after cancer diagnosis. Another study using SEER-Medicare data for the 
years 1998-2002 examined the unadjusted incidence rate of depression among 5,087 elderly 
Medicare beneficiaries (age ≥ 66) with ovarian cancer (6). This study found a 12-month 
depression incidence rate of 65 per 1000 person-years after cancer diagnosis. These studies 
followed individuals over varying periods and, therefore, estimated the incidence rate of 
depression per 1000 person-years. 
1.1.4 Risk Factors for Depression among Cancer Survivors  
Cancer-Related Factors  
 
The stage at cancer diagnosis can increase the risk of developing depression, hereinafter 
referred to as “newly-diagnosed” depression.  A longitudinal study of 500 elderly cancer patients 
(age ≥65) receiving chemotherapy found that advanced stage at cancer diagnosis was 
significantly associated with depression (β=0.83, SE=0.28, P=0.003) (15). An observational 
study using the SEER-Medicare database for the years 1998-2002 among 51,590 elderly 
Medicare beneficiaries (age ≥ 66) with breast cancer found that the risk of depression was higher 
among women with advanced stage at breast cancer diagnosis as compared to those with early-





Cancer treatment type can affect the risk of developing depression. A study among 
women with early-stage breast cancer found that women who received chemotherapy were more 
likely to have a probable case of depression (Odds Ratio (OR) = 2.07; 95% CI: 1.18–3.62) as 
compared to those who did not receive chemotherapy (16). A prospective study among 64 
women with stage I–III breast cancer found a significant association between chemotherapy 
treatment and depression (17). Another prospective study among 32 women with stage I-III 
breast cancer also found a significant association between chemotherapy treatment and 
depression (18). A study among 61 men with prostate cancer found that androgen deprivation 
therapy was associated with depression as compared to those who received surgery (19). Another 
study among men with prostate cancer found that radiotherapy was associated with depression as 
compared to prostatectomy (20). These findings suggest that the risk of developing depression 
may depend on the type of treatment received.  
Socio-demographic Correlates  
 
Socio-demographic factors can also influence the risk of depression among cancer 
survivors. A retrospective cohort study using SEER-Medicare data for elderly Medicare 
beneficiaries with localized prostate cancer found that a higher percentage of men who were 
white (4.8% vs. 3.5%), unmarried (6.6% vs. 3.9%), had low income (5.4% vs. 3.6%), and lived 
in non-metropolitan area (5.5% vs. 4.4%) had diagnosed depression as compared to African 
Americans, married, those who had high income or lived in metropolitan areas (14). Among 
cancer survivors, older age groups had higher rates of diagnosed depression, as compared to 









Pre-existing and co-existing chronic conditions  
 
The number and types of pre-existing chronic conditions may also be associated with 
depression among cancer survivors. A retrospective cohort study using SEER-Medicare data for 
men diagnosed with localized prostate cancer found that men with a higher comorbidity index 
had a significantly higher percentage of depression diagnosis as compared to those with a lower 
comorbidity index (9.1% vs. 3.4%) (14). Anxiety usually co-exists with depression in cancer 
patients. A cross-sectional study of 8,265 adult cancer patients has found that 12.4% of patients 
had co-existing anxiety and depression (16). 
 
1.1.5 Negative Health Consequences of Depression among Elderly Cancer Survivors 
Mortality  
 
Among cancer survivors, the presence of depression is associated with higher all-cause 
mortality (13), cancer-specific mortality (11), and suicide (22). A retrospective cohort study 
using SEER-Medicare data for 50,147 elderly Medicare beneficiaries (age ≥ 66) with prostate 
cancer examined the association between depression and all-cause mortality (13). The 
investigators of this study found that among men with prostate cancer, depression was associated 
with 88% greater all-cause mortality (Hazard Ratio (HR), 1.88; 95 % CI: 1.24–2.83) as 
compared to those without depression. A retrospective cohort study using the SEER-Medicare 
data for 2,199 elderly Medicare beneficiaries (age ≥ 66) with colorectal cancer examined the 
association between depression before cancer diagnosis and cancer-specific mortality (11). This 
study found that those with a depression diagnosis had 25% greater cancer-specific mortality 
(Adjusted Hazard Ratio (AHR) =1.25; 95 % CI: 1.08-1.46) as compared to those without a 





survivors. In a retrospective cohort of 667 elderly men (age ≥65) with prostate cancer, it was 
found that depression was correlated with the risk of suicide (22).  
Health-related Quality of Life (HRQoL) 
 
Depression among cancer survivors has been found to be associated with poor HRQoL 
(23). A cross-sectional study among 240 women with breast cancer (mean age 58) found that 
those who had depression scored significantly lower on all HRQoL subscales that measured 
cognitive, emotional, role, physical, and social functioning, and overall HRQoL compared to 
those without depression (23).  
Healthcare Utilization and Expenditures  
 
The cost of cancer in the United States is projected to increase from $124 billion to $173 
billion by 2020, a 39% increase from 2010 (24). This increase is due to improving survival, new 
cancer treatments, and the growth and aging of the population. The financial burden can also 
vary by the type of cancer. For example, the estimated cost of cancer was highest for breast 
cancer ($16.5 billion), colorectal cancer ($14 billion), followed by prostate cancer ($12 billion) 
(25). 
Depression among cancer survivors can further increase the financial burden. It is 
reported that elderly individuals with cancer and depression had higher healthcare utilization and 
expenditures as compared to their counterparts without depression (13,26). A study using SEER-
Medicare data for the years 1995-2003 examined the association between depression and 
healthcare utilization and expenditures among 4,285 elderly (age >66) with prostate cancer and 
depression (13). This study found that elderly with both cancer and depression were more likely 
to have emergency room visits (Adjusted odds ratio (AOR) =3.5, 95% CI: 3.2-4.3.7), inpatient 





without depression.  In addition, this study found that during all phases of cancer (treatment, 
follow-up, and terminal phase) prostate cancer patients with depression had higher total 
healthcare expenditures as compared to those without depression. For example, during the 
treatment phase, depression among elderly with prostate cancer was associated with higher total 
health expenditures ($27,500 vs. $20,000) as compared to those without depression. Another 
study using claims data for the years 2006-2007 examined the association between depression 
and health care expenditures among 11,014 non-elderly military healthcare beneficiaries (ages 
18-64) with different types of cancer and newly-diagnosed depression (26). This study found that 
those diagnosed with depression had a significantly higher healthcare utilization for inpatient 
visits (mean: 3.2 vs. 0.6), outpatient visits (mean: 33.7 vs. 18.7), and medication use (mean: 45.3 
vs. 24.5). This study also found that depression among cancer survivors was associated with a 
110% increase in total health expenditures ($16,212 vs. $7,728, p-value<0.05) as compared to 
those without depression. 
1.1.6 Depression and Cancer Treatment  
Depression may affect the choice of cancer treatment, which may, in turn, affect cancer 
outcomes. A retrospective cohort study using SEER-Medicare data for elderly Medicare 
beneficiaries with colorectal cancer found that those with depression were less likely to receive 
chemotherapy (AOR= 0.67; 95% CI: 0.48-0.92) as compared to those without depression (11). A 
cross-sectional study among 117 women with breast cancer (ages 28-72) found that those with 
depression had a significantly lower acceptance for receiving adjuvant chemotherapy as 
compared to those without depression (51.3% vs. 92.2%, P<0.0001) (27). An observational study 
using SEER-Medicare data among 24,698 elderly women with breast cancer found that women 
with depression were more likely to receive non-definitive cancer treatment as compared to those 





observational study using SEER-Medicare data on men with localized prostate cancer found that 
those with pre-existing depression were less likely to undergo definitive treatment (surgery or 
radiation) as compared to those without a depression diagnosis (14). 
 
1.1.7 Depression Treatment  
Modalities of Depression Treatment 
 
While depression has many negative consequences, it is a treatable chronic illness (3). 
Relief from depression can be achieved with either pharmacotherapy, psychotherapy or a 
combination of pharmacotherapy and psychotherapy (American Psychiatric Association, 2010). 
Pharmacotherapy typically consists of antidepressants such as Selective Serotonin Reuptake 
Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic 
Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs) and others (mirtazapine, 
bupropion) (5). The selection of antidepressant medication depends on concurrent chronic 
conditions, the safety and the side-effects profile of the antidepressant, pharmacological 
properties (drug interaction) and patient preference.  
Depression can also be treated with psychotherapy. Psychotherapy can take different 
forms and be provided in group or individual settings. These therapies consist of cognitive-
behavioral therapy (CBT), interpersonal therapy, psychodynamic therapy, and problem-solving 
therapy (PST) (5). Factors that can affect the choice of using psychotherapy can include the 
severity of depression, availability and affordability of psychotherapy, and patient preferences.  
Efficacy of Antidepressants in Treating Depression among Elderly  
 
A case needs to be made for the efficacy of depression treatment among the elderly (age 
> 65 years) because cancer is often considered the disease of the elderly (2).  The median age at 





However, there is uncertainty about the efficacy of antidepressants in adults 65 years and older 
(30,31). A meta-analysis of 6 double-blind RCTs involving 1,840 patients aged 65 years and 
older examined the efficacy of antidepressants in treating depression (30). The investigators of 
this meta-analysis concluded that there were no statistically significant differences between the 
treatment groups and the placebo groups (Relative Risk (RR) = 1.13; 95% CI: 0.93–1.37, p = 
0.265). The efficacy of antidepressants in treating depression among adults aged 60 years and 
older was also examined in a meta-regression of 34 double-blind RCTs (31). Findings from this 
meta-regression revealed that at 12-week follow-up, older age was associated with lower 
response to antidepressants. 
Efficacy of Antidepressants in Treating Depression among Adult Cancer Survivors 
 
There have been few RCTs that examined the efficacy of antidepressants in treating 
depression among cancer survivors. The efficacy of antidepressants in all of these clinical trials 
was defined as a reduction in depressive symptoms scores. A 4-week RCT compared mianserin, 
a TCA, to a placebo in 73 women with depression and different types of cancer (32). This study 
found a significant reduction in depression score from baseline on the HDRS rating scale in the 
mianserin group as compared to the placebo at week 4 of depression treatment. A 6-week RCT 
among 55 women with both early stage breast cancer and depression compared mianserin to a 
placebo (33). This study found a significant reduction in depression score from baseline on the 
HDRS rating scale in the mianserin group as compared to the placebo at four and six-week 
follow-up periods. A 6-week RCT among 40 women with depression and different types of 
cancer assigned them to either fluoxetine or desipramine or placebo (34). The investigators found 
a significant reduction in depression score from baseline on the HDRS rating scale in both the 





In contrast, a 5-week RCT among 115 cancer patients with depression and different types 
of cancer compared fluoxetine, an SSRI, to a placebo (35). This trial found no significant 
reduction in depression scores from baseline on the HADS rating scale between the fluoxetine 
group and the placebo. A 6-week RCT among 35 women with breast cancer compared 
paroxetine, an SSRI, or desipramine, a TCA, to a placebo (36). The investigators did not find a 
significant reduction in depression score from baseline on the HDRS rating scale between the 
treatment groups and the placebo. Laoutidis & Mathiak conducted a meta-analysis of six RCTs 
that examined the efficacy of antidepressants in patients with cancer (37). Based on this meta-
analysis, the investigators found that patients who used antidepressants were 50% more likely to 
achieve a therapeutic response compared to the placebo (RR = 1.56, 95% CI: 1.07 – 2.28). 
However, these investigators concluded that due to the small number of patients and lack of 
clarity in the risk of bias, the findings cannot be used to recommend antidepressant therapy for 
treating depression among cancer patients. 
In summary, RCTs have shown mixed results on the efficacy of antidepressants among 
cancer patients even with the same type of antidepressants. In, addition, there are no studies on 
the efficacy of antidepressants in elderly cancer survivors. Even when antidepressant usage was 
examined among elderly individuals in general (age ≥ 65), antidepressants were not found to be 
efficacious in treating depression among the elderly. As cancer is often diagnosed in the elderly 
population (2) and the efficacy of antidepressants among elderly individuals is questionable, one 











Efficacy of Psychotherapy in Treating Depression among Elderly Individuals 
 
RCTs have shown all types of psychotherapy to be efficacious in the short-term among 
individuals aged 50 and older (38). A RCT among 44 elderly (age ≥ 60) individuals with 
depression compared CBT versus usual care (39). This study found a significantly lower 
percentage of individuals with depressive symptoms in the CBT group as compared to usual care 
at the 18 weeks follow-up period (26% vs. 58%, p=0.05). A meta-analysis of 27 RCTs involving 
2,245 patients 55 years and older compared psychotherapy treatment to control groups (waiting-
list, usual care, attention, supportive therapy, and placebo) (38). This meta-analysis included 
different types of psychotherapy with varying observation periods (4 to 26 weeks) and varying 
numbers of psychotherapy sessions (4 to 12 sessions). The results from this meta-analysis 
revealed that psychotherapy was effective in reducing depression scores as compared to control 
groups (Standardized mean differences (SMD): 0.73; 95% CI: 0.51-0.95, p <0.00001). In this 
meta-analysis, a subgroup analysis of individuals who were aged 60 and above revealed similar 
results. Another meta-analysis of 44 RCTs involving 4,409 patients aged 50 and older compared 
psychotherapy to control groups (waiting-list, usual care, attention, supportive therapy, 
pharmacotherapy, and placebo) (40). In this meta-analysis, psychotherapy was found to be 
effective compared to the control groups (Hedge’s g: 0.64; 95% CI: 0.47-0.80). The above-
mentioned RCTs and meta-analysis of RCTs indicate that psychotherapy is effective in treating 
depression in elderly individuals. 
 
Efficacy of Psychotherapy in Treating Depression among Adult Cancer Survivors 
 
Few RCTs have examined the efficacy of psychotherapy in cancer patients. The most 
commonly examined forms of psychotherapy among cancer patients include CBT and supportive 





of breast cancer and depressive symptoms compared 8-week sessions of individual CBT with 
three booster sessions to a waiting-list control (41). The study findings showed a significant 
reduction in depression score from baseline on the HDRS rating scale in the CBT group as 
compared to a waiting-list control. Another RCT compared group CBT to a waiting-list control 
group among 62 women with breast cancer (42). This trial found that patients receiving group 
CBT achieved a significantly greater reduction in the depression score from baseline as 
compared to the control group. In a RCT of 88 women with breast cancer, women were 
randomized to 6-week sessions of group CBT or usual psychosocial care (43). The investigators 
found that women in the CBT group had lower rates of depression compared to the control group 
at six weeks follow-up (6.5% vs. 10.4%, p<0.05). A RCT involving 458 women with metastatic 
breast cancer compared weekly group supportive therapy to no therapy. The study found lower 
rates of depression in group supportive therapy as compared to the control group at a six months 
follow-up period (18% vs. 40%, p=0.002) (44). A meta-analysis of six RCTs, which involved 
1,362 participants with mixed types of cancer, compared psychotherapies (PST, CBT) to control 
groups (wait-list, usual care). This meta-analysis found that psychotherapy interventions were 
more efficacious than the control groups (45). 
To summarize, although studies among elderly, in general, did not specifically focus on 
individuals aged 65 and older, all types of psychotherapy have been found to be efficacious in 
the short-term among individuals aged 50 and older. In addition, studies among adult cancer 
survivors revealed that psychotherapy is efficacious in the short-term.  However, none of these 







Efficacy of Combined Antidepressants and Psychotherapy in Treating Depression among Elderly  
 
There is a limited number of RCTs on the combination of psychotherapy and 
antidepressants compared with mono-therapies for the treatment of depression in the elderly. A 
12-week RCT of 102 elderly with depression compared combination therapy (desipramine + 
CBT) with antidepressant only (desipramine) and CBT only (46). The findings of this trial show 
a greater reduction in depressive symptoms for the “combination therapy” group as compared to 
antidepressants only. However, there were no differences between combination therapy and CBT 
only. A double-blind RCT among 80 ambulatory older adults (age >50) examined the efficacy of 
combined IPT and nortriptyline versus a placebo and IPT group for treating bereavement-related 
major depressive episodes (47). This study found that the remission rate for nortriptyline plus 
IPT was higher than for the placebo plus IPT (69% vs. 29%).  
 
Efficacy of Combined Antidepressants and Psychotherapy in Treating Depression among Cancer 
Survivors 
 
There is limited research on the efficacy of combination therapy, with antidepressants 
and psychotherapy, in treating depression among cancer patients. To our knowledge, only one 
RCT examined the efficacy of combination therapy among cancer survivors in usual care 
settings. A RCT of 72 adult cancer patients (non-elderly) with depression has compared a 
narrative therapy (NT) plus escitalopram group to a escitalopram plus usual care group (48). This 
study found no significant difference in depressive symptoms between the two groups.  
The above-mentioned RCTs provide some evidence for the efficacy of combination 
therapy as compared to mono-therapy in treating depression among the elderly. However, none 
of these studies examined the efficacy of combination therapy in treating depression among 





Clinical Practice Guidelines for Treating Depression in Cancer Survivors 
 
Despite mixed evidence regarding the efficacy of antidepressants and psychotherapy for 
treating depression in cancer patients, practice guidelines have been developed for treating 
depression in cancer patients (49,50). A guideline was established by the Supportive Care 
Guidelines Group from Canada based on a systematic review of the published literature through 
June 2005 (50). This guideline recommends antidepressants to cancer patients with moderate to 
severe major depression. However, this guideline does not prioritize antidepressants over 
psychosocial interventions, nor one antidepressant over another. Another Canadian guideline was 
developed in 2010 through a collaboration between the Canadian Partnership against Cancer and 
the Canadian Association of Psychosocial Oncology (CAPO) (49). This guideline was adopted 
by the American Society of Clinical Oncology (ASCO) in 2014 (51). In this guideline, there is 
no recommendation about any antidepressants being better than the other and it recommends that 
the selection of antidepressants should be based on side-effect profile, drug interaction, patient 
age, and patient preference.  
The American Psychiatric Association (APA) guideline recommends treatment of 
depression in all adults and includes specific recommendations for the elderly (5). According to 
the APA, depression treatment needs to be considered in three phases: an acute phase to attain 
remission of symptoms, a continuation phase to prevent a relapse, and a maintenance phase to 
prevent a recurrence. This guideline recommended a period of 4-8 weeks to assess the 
effectiveness of treatment in the acute phase of treatment. If patients respond to treatment in the 
acute phase, then the guideline recommends that they should continue the treatment for 4 to 9 
months (continuation phase). A maintenance phase is required to prevent a relapse for patients at 






Depression Treatment in Real-World Clinical Practice Settings 
 
Depression treatment among cancer survivors has been examined with a few studies. A 
cross-sectional study using the Medicare Current Beneficiary Survey (MCBS) from 2000-2005 
examined the rate of antidepressant use among 865 elderly (age ≥ 65) with both cancer and 
depression. The investigators found that among elderly with both cancer and depression, 57% 
received antidepressants only, 19% received psychotherapy with or without antidepressants, and 
24% did not receive any depression treatment (52). Another cross-sectional study using the 
Medical Expenditures Panel Survey (MEPS) from multiple years, 2006-2008, examined 
depression treatment among 528 adults (both elderly and non-elderly) with both cancer and 
depression (53). This study estimated that 17% of elderly cancer patients with depression did not 
receive any depression treatment (defined as antidepressants with or without psychotherapy). 
These studies indicate that no treatment for depression can range from 17% to as high as 24% of 
elderly with both cancer and depression.  
1.2 Need for the Study 
  
Based on our review of the existing literature on depression among cancer patients, 
studies on the incidence of depression after cancer diagnosis are sparse. To date, there have been 
only two studies that examined the incidence of depression among cancer survivors (6,7). These 
studies suggested that the incidence of depression within 12 months after the cancer diagnosis is 
24 per 1000 person-years for women with breast cancer and 65 per 1000 person-years for women 
with ovarian cancer. While these studies contributed to the knowledge-base for incidence of 
depression among women with breast and ovarian cancer, none of them examined the risk of 
developing depression in colorectal and prostate cancer patients, thus, a knowledge-gap exists. 





(women breast cancer vs. women colorectal cancer and men prostate cancer vs. male colorectal 
cancer). 
There is also a paucity of research on depression treatment in elderly cancer patients with 
newly-diagnosed depression after a cancer diagnosis. Only two studies in the United States have 
examined depression treatment in elderly cancer patients with a depression diagnosis (52,53). 
These studies indicate that no treatment for depression for elderly with both cancer and clinical 
depression can range from 17% to as high as 24%. However, these studies were limited to 
examining any depression treatment (53) and did not examine treatment with psychotherapy only 
(52). In addition, both studies examined depression treatment among elderly with any cancer and 
did not distinguish between types of cancer and non of these controlled for cancer related factors 
such as stage at cancer diagnosis and cancer treatment. It is unknown how depression is treated 
for distinct types of cancer. In addition, the subgroup differences in depression treatment among 
elderly with breast, colorectal or prostate cancer is unknown, therefore, a knowledge-gap exists. 
Further, there is evidence that depression among cancer patients is associated with 
increased financial burden. Studies have shown that depression among cancer patients was 
associated with a 37.5% to 110% increase in total health care expenditures as compared to the 
expenditures of those without depression (13,26). Depression treatment can be a pathway to 
reduce healthcare utilization and expenditures as it has been shown to reduce depressive 
symptoms and to improve the quality of life for cancer survivors (54,55). There are no studies 
that examined the association between depression treatment and healthcare expenditures among 
cancer survivors with newly-diagnosed depression in a usual care setting, thus, a knowledge-gap 
exists. Therefore, the current dissertation will address these gaps in knowledge among elderly 





selection of these cancer types is discussed in the Methods section.  The study has the following 
specific aims, objectives, and hypotheses. 
 




Investigate the risk of newly-diagnosed depression among elderly Medicare beneficiaries 
with incident breast, colorectal or prostate cancer.  
Objective 1.1 
 
Estimate the rates of newly-diagnosed depression by cancer types (breast vs. female colorectal 
and prostate vs. male colorectal cancer) among elderly Medicare beneficiaries who have incident 
breast, prostate or colorectal cancer. 
Objective 1.2 
 
Examine the risk of newly-diagnosed depression by cancer types (breast vs. female colorectal 
and prostate vs. male colorectal cancer), after controlling for other risk factors, among elderly 
Medicare beneficiaries who have incident breast, prostate or colorectal cancer. 
Hypothesis 1.2 
 
Among cancer patients, women with colorectal cancer will be more likely to be 
diagnosed with incident depression as compared to women with breast cancer; men with 
colorectal cancer will be more likely to be diagnosed with incident depression as 











Aim 2  
 
Examine the rates and factors associated with depression treatment among elderly 




Estimate the rates of depression treatment among elderly Medicare beneficiaries with newly-
diagnosed depression and incident breast, colorectal or prostate cancer. 
Objective 2.2 
 
Examine the predisposing, enabling, need, and external environment factors associated with 
depression treatment among elderly Medicare beneficiaries with newly-diagnosed depression 
and incident breast, colorectal or prostate cancer. 
Hypothesis 2.2  
 




Examine the association between depression treatment and total healthcare expenditures 
among elderly Medicare beneficiaries with newly-diagnosed depression and incident 




Estimate total and types of healthcare expenditures by depression treatment categories among 









Evaluate the relationship between depression treatment categories and total and types of 
healthcare expenditures among elderly with newly-diagnosed depression and incident breast, 




The short-term total healthcare expenditures will be higher among elderly who received 
depression treatment compared to those who received no treatment. 
 
1.4 Data Source 
 
1.4.1 Surveillance, Epidemiology and End Results (SEER)  
The SEER Program is an epidemiologic surveillance system consisting of population-
based tumor registries residing in 18 SEER areas  (Atlanta, Connecticut, Detroit, Hawaii, Iowa, 
New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles and San Jose-
Monterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana, New Jersey, 
and Greater Georgia) (56). SEER cancer registries collect data on all incident cases of cancer that 
occur in persons residing in SEER areas. These data are available in the Patient Entitlement and 
Diagnosis Summary File (PEDSF) file which has information on a patient’s demographic 
characteristics, cancer type, tumor characteristics, and chemotherapy and radiation therapy 
provided within four months of cancer diagnosis.  
1.4.2 Medicare  
As Medicare is the primary health insurer for the elderly, SEER data have been linked to 
Medicare claims. SEER has been linked to Medicare using an algorithm based on the patient first 





older in the SEER files has been matched to the Medicare enrollment file (57). Most of Medicare 
beneficiaries receive Medicare Part A and B coverage. Part A of the Medicare program covers 
the following types of services: inpatient hospitalization, Skilled Nursing Facility (SNF), home 
health services following hospital stay (HHA) and hospice care. Part B of the Medicare program 
covers the following types of services: physician services, outpatient services, diagnostic tests, 
Durable Medical Equipment (DME), emergency room visits, home health care not following a 
hospital stay, laboratory services, and other medical services. Medicare program also covers 
prescription drugs, Medicare Part D. Medicare data does not include all the claims for the 
beneficiaries enrolled under the Health Maintenance Organizations (HMOs) as the organizations 
are not required to submit all their services claims to Center for Medicare and Medicaid (CMS). 
Medicare claims files consist of inpatient claims (Medicare Provider Analysis and Review 
(MEDPAR), outpatient claims (National Claims History (NCH) and Outpatient Claims Files 
(OUTSAF)), Durable Medical Equipment (DME), Home Health Agency (HHA) as well as a 
prescription drug file (PDESAF). In the current study, this study utilized data from the PEDSF 
file linked with MEDPAR, OUTSAF, and NCH, HHA and PDESAF files for the years 2007 to 
2012. 
1.4.3 American Community Survey (ACS) Estimates from Census 
This study used the ACS 2008 to 2012 census tract and census zip code files. These files 
were linked to PEDSF files by geographic codes, which included state and county. These files 
were used to derive the census tract median household income and education level. 
1.4.4 The Area Health Resource File (AHRF) 
The AHRF is a publicly available data file provided by Department of Health and Human 
Services; it includes county, state and national files (58). The AHRF provides more than 6,000 





health professions, and socioeconomic and environmental characteristics. The AHRF was used 
to provide county-level urban/rural continuum codes, percentage of psychologists, and on the 
presence of community mental health clinics. The AHRF files were linked to PEDSF files by 
geographic codes, which included state and county.  
1.5 Rationale for Cancer Selection 
 
This dissertation included breast, colorectal or prostate cancers because they are projected 
to be the most common types of cancer by 2024; breast cancer among women (41%), prostate 
cancer among men (45%), and colorectal cancer among men and women (8%) (29). In addition, 
depression is highly prevalent in these cancer types (9,11-13). In this dissertation, depression 
incidence and depression treatment were compared within gender-specific cancers (women 
breast vs. women colorectal cancer and men prostate vs. men colorectal cancer). 
Depression incidence and depression treatment may not be similar among these types of 
cancer due to differences in survival prognosis and stage at the time of cancer diagnosis. With 
regard to cancer survival, survival prognosis may affect the risk of developing depression and 
depression treatment, and it is well documented that survival rates vary by types of cancer. The 
estimated 5-year relative survival rate is 89% for women with breast cancer, 99% for patients 
diagnosed with prostate cancer and 65% for patients with colorectal cancer (29). With regard to 
the stage at cancer diagnosis, the differences in the stage of cancer at the time of cancer diagnosis 
can affect the risk of depression. Danese and colleagues found that the risk of depression among 
women with breast cancer was higher among women diagnosed at an advanced stage of cancer 
compared to those diagnosed at an early stage of breast cancer (Stage IV: 17% vs. Stage I: 3%) 
(7). Colorectal cancer is usually diagnosed at a late stage as compared to breast and prostate 





focused on the treatment of cancers that have lower survival rates and are diagnosed at late stage 
rather than on the recognition and management of other co-existing conditions such as 
depression.  
 
1.6 Rationale for Selection of Elderly Individuals 
 
This dissertation focused on elderly individuals with breast, colorectal or prostate cancer. 
Elderly individuals were selected because cancer is the disease of the elderly; 72% of breast 
cancer, 82% of colorectal cancer, and 90% of prostate cancer patients were 60 years and older 
(29). In addition, as 97% of the US population aged 65 years and older are covered by Medicare, 
which is the US government mandated insurance program, this study used inpatient, outpatient, 
prescription drugs claims that were linked to cancer related information from PEDSF file. 
 
1.7 Conceptual Framework 
 
 The first aim of the current dissertation adapted the determinants-of-health model by 
Marmot and Wilkinson (1999) (59). This model posits that many dimensions affect an 
individual’s health or disease/illness (e.g., newly-diagnosed depression). These dimensions are 1) 
Individual physical makeup variables included age in years at cancer diagnosis, and 
race/ethnicity; 2) Social Support was marital status; 3) Access to care was measured by Primary 
Care Physicians (PCP) visit, census-tract median household income, and percentage with less 
than high school education level; 4) Health behavior consisted of tobacco use; 5) Psychological 
factors included anxiety; 6) Biological risk factors were the stage of cancer at diagnosis and 
chronic physical conditions during; 7) Treatment factors included cancer treatment; 8) 
Community Resources consisted of the presence or absence of county-level community mental 





professional shortage area (HPSA) for mental health; 8) Geographical location consisted of the 
SEER region, and county metro status. To control for changes in patterns of diagnosis over time, 
year of cancer diagnosis was also included. 
The second and third aim of the current dissertation used the expanded behavioral model 
on healthcare utilization, the Andersen Behavioral Model, to help in our selection of variables 
that may affect health care utilization (Figure 1) (60). For the second aim, according to this 
model, depression treatment (i.e. health services utilization) is a function of: 1) an individual’s 
predisposition to utilize the services – predisposing factors (age, race/ethnicity); 2) factors which 
enable individuals to use healthcare services – enabling factors (marital status, PCP visits, cancer 
type, cancer stage, cancer treatment) 3) an individual’s level of need – need factors (chronic 
conditions) and 4) the external environment.  
 For the third aim, according to this model, healthcare expenditures varies as a function of 
1) predisposing factors – age and race; 2) enabling factors: cancer type, cancer stage, cancer 
treatment, marital status and PCP visits; 3) need factors – depression treatment, the number of 
chronic physical and mental health conditions; and 4) the external environment: SEER region 























































Demographics: age, and race/ethnicity 
Enabling factors 
Marital status, and census tract 
socioeconomic factors (median household 
income, % with college education) 
Need factors 
Chronic physical conditions, mental 




External environment factors 
 SEER region, area of residence (metro/non-
metro), county level % of psychologists and 
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STRUCTURE OF THIS DISSERTATION 
 
The current dissertation was organized as follows: Chapter One reviews the current literature on 
depression diagnosis among elderly with cancer and provides a justification for the aims of the 
current dissertation. Furthermore, Chapter One describes the data sources, provides the rationale 
for the selection of cancer types and the conceptual frameworks that guide the selection of 
variables in the current dissertation. The methods to conduct the studies of the current 
dissertation are described in each chapter. Chapter Two focuses on the risk of newly-diagnosed 
depression among elderly with incident cancer; Chapter Three focuses on the rates and factors 
associated with depression treatment among elderly with newly-diagnosed depression and 
incident cancer; Chapter Four focuses on the association between depression treatment and short-
term healthcare expenditures among elderly with newly-diagnosed depression and incident 
cancer. Finally, Chapter Five includes a summary of findings, implications, strengths and 













Chapter 2   
Cancer Types and the Risk of Newly-Diagnosed Depression among Elderly 





Elderly individuals (age > 65 years) with cancer are at high risk for newly-diagnosed depression 
after cancer diagnosis. It is not known whether the risk of newly-diagnosed depression varies by 
cancer type. Therefore, this study examined the variations in the risk of newly-diagnosed 
depression by cancer types among elderly individuals with cancer.  
Patients and Methods 
This study utilized a retrospective cohort study design and used data from the linked 
Surveillance, Epidemiology and End Results (SEER)-Medicare files. Elderly individuals (age > 
65 years) with incident breast, colorectal, and prostate cancer diagnosed between 2007 and 2011 
(N = 53,821) were followed for 12 months after cancer diagnosis. The risk of newly-diagnosed 
depression after cancer diagnosis was identified using the International Classification of 
Diseases, 9th Edition, Clinical Modification (ICD-9-CM) Codes. Complementary log-log 
regression was used to examine the association between cancer types and the risk of newly-
diagnosed depression after adjusting for other risk factors for depression.  
Results 
This study found a significantly higher percentage of newly-diagnosed depression among women 
with colorectal cancer as compared to women with breast cancer (5.8% vs. 3.9%), and among 
men with colorectal cancer as compared to men with prostate cancer (3.4% vs. 1.6%). In the 
adjusted analysis, women with colorectal cancer had 28.0% higher risk of newly-diagnosed 





[95%CI, 1.12-1.46]) and men with colorectal cancer had 106.0% higher risk of newly-diagnosed 
depression as compared to men with prostate cancer (ARR =2.06 [95% CI, 1.65-2.58]).  
Conclusion 
The study findings identified cancer types with a high risk of newly-diagnosed depression after 
cancer diagnosis who might benefit from routine depression screening and monitoring to help in 
early detection and treatment of depression.  























Depression is a highly prevalent mental health condition among elderly cancer survivors. 
It is estimated that 5-25% of cancer survivors suffer from depression (1-5). Further, the risk of 
newly-diagnosed depression is higher among cancer survivors when compared to age-sex 
matched non-cancer cohorts, as two retrospective studies have shown (6,7). One study using the 
Surveillance Epidemiology and End Results (SEER)-Medicare data found that women with 
breast cancer had 58% higher risk of newly-diagnosed depression within a year after cancer 
diagnosis as compared to their matched non-cancer counterparts (Adjusted Risk Ratio 
(ARR)=1.58; 95%CI, 0.84-3.0) (6). A second study, among adults with different cancer types 
found that men with colorectal cancer had 67% higher risk of newly-diagnosed depression as 
compared to their age-sex matched non-cancer cohort (Risk Ratio (RR)=1.16; 95% CI, 0.90-
1.51) (7).   
The risk of newly-diagnosed depression maybe higher among some cancer types as 
compared to others due to differences in survival prognosis and stage at cancer diagnosis (6,8). 
The estimated 5-year relative survival rate is 65% for individuals with colorectal cancer as 
compared to 89% for women with breast cancer and 99% for men with prostate cancer (8). 
Danese and colleagues found that elderly women with breast cancer diagnosed at an advanced 
stage (stage IV) had a higher risk of newly-diagnosed depression as compared to those diagnosed 
at an early stage (Stage I) (RR= 5.03, 95%CI = 3.45-7.35) (6). Colorectal cancer is more likely to 
be diagnosed at an advanced stage and to have a poor survival prognosis as compared to breast 
and prostate cancers (6,8).  Therefore, colorectal cancer patients may have a higher risk of 





Although the risk of newly-diagnosed depression may vary by cancer type, there is a 
paucity of research on the variations in the risk of newly-diagnosed depression by cancer type. 
Identifying cancer survivors, who are at high risk of newly-diagnosed depression, is important 
because depression can negatively affect the health-related quality of life (HRQoL) and survival 
after cancer diagnosis (1,3,9). Therefore, the objective of this study was to examine the 
variations in the risk of newly-diagnosed depression by cancer types among elderly Medicare 
beneficiaries with incident breast, colorectal and prostate cancer. These cancers were selected 
because they are projected to be the most common cancer types by 2024 and in which depression 
is highly prevalent (8). This study evaluated the risk of newly-diagnosed depression by cancer 
types with the following comparisons: women with breast cancer compared to women with 
colorectal and men with prostate cancer compared to men with colorectal cancer.   
2.3 Conceptual Framework  
 
This study adapted the determinants-of-health model by Marmot and Wilkinson (1999) 
(10). This model posits that many dimensions affect an individual’s health or disease/illness 
(e.g., newly-diagnosed depression). These dimensions are an individual’s physical make-up, 
social support, access to care, health behaviors, psychological factors, biological risk factors, 
treatment factors, community resources, and geographical region. 
2.4 Methods 
 
2.4.1 Data Sources 
 The current study linked data from several sources including the SEER-Medicare linked 
database, ACS estimates from census, and the AHRF files. The detailed description of the data 





2.4.2 Study Design 
This study utilized a retrospective cohort study design with a baseline and follow-up 
period. It considered the date of cancer diagnosis as the index date. This study defined the 12 
months before the index date as the baseline period and the 12 months after index date as the 
follow-up period.  
2.4.3 Study population 
Identification of Cancer Survivors 
The study population composed of elderly cancer patients, age 66 years and older who 
were diagnosed with primary only incident breast, colorectal, and prostate cancer between 2007 
and 2011. An age of 66 years and above was imposed to allow 12-month baseline period before 
cancer diagnosis. The cancer types (breast, colorectal and prostate cancer) were identified using 
the primary site variable and the International Classification of Diseases for Oncology, 3rd 
Edition (ICD-O-3) histology codes.  
Depression-free Individuals at Cancer Diagnosis  
This study identified a depression-free cohort among individuals with incident cancer. To 
ensure that the incident cancer cases were depression free, a validated criteria from the National 
Committee for Quality Assurance (NCQA) was used (13). According to the NCQA, an 
individual is considered to be depression-free at index date, if he or she did not receive 
antidepressants 90 days before the index date (i.e. date of cancer diagnosis) or did not have any 
depression diagnosis 120 days before the index date.  
Other inclusion/exclusion criteria  
This study required that all individuals have continuous enrollment in Medicare part A, B 
and no enrollment in managed care plans during the baseline and follow-up periods. To identify 





continuous enrollment in Medicare part D three months before cancer diagnosis. This study 
excluded individuals with an unknown stage at diagnosis or those diagnosed through autopsy or 
death certificate, and those who died during the follow-up period of 12 months. Appendix 2.1 
demonstrates the analytical population selection process. 
2.4.4 Dependent Variable: Newly-diagnosed Depression (Yes/No) 
The dependent variable was newly-diagnosed depression after cancer diagnosis (newly-
diagnosed depression) in breast, colorectal and prostate cancer survivors. To identify depression 
diagnosis, a validated algorithm developed by the Centers for Medicare and Medicaid Services 
(CMS) Chronic Conditions Data Warehouse (CCW) was used (14). Individuals with at least one 
inpatient visit or one outpatient visit with depression diagnosis during the 12 month follow-up 
period were classified as having a newly-diagnosed depression. This study identified depression 
diagnosis using the International Classifications of Diseases – 9th edition, Clinical Modification 
Codes (ICD-9-CM). The ICD-9-CM codes were: 296.2 , 296.3, 298.0, 300.4, 309.1, and 311.0. 
These codes are widely used to identify depression diagnoses among Medicare beneficiaries 
(1,15,16).   
2.4.5 Key Independent Variable 
This study selected the independent variables based on the Determinants of Health 
Model. The key independent variable was cancer types which is considered a biological risk 
factor. Cancer types were: women with breast cancer, women with colorectal cancer, men with 







2.4.6 Other Independent Variables  
Individual physical makeup variables included age in years at cancer diagnosis (66-69, 
70-74, 75-79, >=80), and race (White, African American, Hispanic, and others). Social Support 
included marital status (married, divorced/separated/widow and never married). Access to care 
was measured by Primary Care Physicians (PCP) visit quartiles during 12 months before cancer 
diagnosis, census-tract median household income quartiles, and percentage with less than high 
school education level quartiles. Health behavior consisted of tobacco use in the baseline period. 
Psychological factors included the presence of anxiety during the baseline period. Biological risk 
factors were: the stage of cancer at diagnosis (based the American Joint Committee on Cancer 
(AJCC) grouped staging) and chronic physical conditions during the baseline period. The 
chronic conditions categories included: cardiovascular disease (heart disease (cardiac arrythmia, 
coronary heart disease, congestive heart faliure), diabetes, hyperlipidemia, hypertension, stroke), 
respiratory disease (asthma, chronic obstructive pulmonary disease), and musculoskeletal disease 
(arthritis, and osteoporosis) (17). These conditions were selected based on the Multiple Chronic 
Conditions working group framework for research, planning, programs and policy purposes (17). 
These conditions were identified based on a validated algorithm developed by the CMS Chronic 
Conditions Data Warehouse (14); individuals had at least one inpatient visit or two outpatient 
visits during the baseline period. Treatment factors included cancer treatment during the six 
months after cancer diagnosis which included chemotherapy, radiation therapy, hormone 
therapy, and surgery. Cancer treatment was identified from claims data using the ICD-9-CM, 
Health Healthcare Common Procedure Coding System (HCPCS) and the Common Procedural 
Terminology (CPT) codes. Community Resources consisted of the presence or absence of 
county-level community mental health clinics (CMHC) and whether the county of residence was 





consisted of the SEER region (Northeast, South, North-central, West), and county metro status 
(metro/non-metro) which was defined using 2013 urban/rural continuum codes from the United 
States Department of Agriculture’s Economic Research Service. To control for changes in 
patterns of diagnosis over time, year of cancer diagnosis was also included as one of the 
independent variables. 
2.5 Statistical Analysis 
 
This study used chi-square tests to test the significance of unadjusted differences in 
baseline characteristics and newly-diagnosed depression. A complementary log-log regressions 
analysis were used to examine the adjusted associations between cancer types and the risk of 
newly-diagnosed depression with four different models. In model I, only cancer types was 
included without controlling for other factors. Model II controlled for individual physical make-
up (e.g., age, race) and social support. Model III additionally controlled for access to care, health 
behaviors, biological risk factors, and psychological factors. Model 4 additionally controlled for 
treatment factors, county-level community resources, geographical region, and the year at cancer 
diagnosis. All statistical analyses were carried out in SAS 9.4 (SAS Institute Inc., Cary, NC).  
2.6 RESULTS 
 
2.6.1 Characteristics of the study population 
The study population consisted of 53,821 elderly fee-for-service Medicare beneficiaries 
with incident breast, colorectal, and prostate cancer who were depression-free at the time of 
cancer diagnosis. In the study populations, 36.4% were women with breast cancer; 12.5% were 
women with colorectal cancer; 9.5% were men with colorectal cancer, and 41.6% were men with 
prostate cancer (data not shown in tabular form). The majority of the study population were 





the counties had a shortage of mental health professionals and 48.9% did not have community 
mental health centers.  
2.6.2 Cancer types and newly-diagnosed depression 
Overall, 3.3% of elderly Medicare with breast, colorectal and prostate cancer had newly-
diagnosed depression during the follow-up year. A chi-square analysis showed that newly-
diagnosed depression rates significantly differed by cancer types (P<0.001) (Table 2). This study 
found a significantly higher percentage of newly-diagnosed depression among women with 
colorectal cancer as compared to women with breast cancer (5.8% vs. 3.9%), and among men 
with colorectal cancer as compared to men with prostate cancer (3.4% vs. 1.6%).  
Tables 3 displays the risk ratios (RR) and adjusted RR (ARR) of newly-diagnosed 
depression by cancer types from multivariable complementary log-log regression analyses. In 
model 1, which included only cancer types, women with colorectal cancer had a 53% higher risk 
of newly-diagnosed depression (RR= 1.53 [95%CI, 1.36-1.73]) as compared to women with 
breast cancer; men with colorectal cancer had a 111% higher risk of newly-diagnosed 
depression(ARR= 2.11 [95% CI, 1.76-2.53]) as compared to men with prostate cancer. This 
association between cancer types and the risk of newly-diagnosed depression persisted in Models 
II to IV.  Even after controlling for all the risk factors and the year at cancer diagnosis in the final 
model, women with colorectal cancer had 28% higher risk of newly-diagnosed depression (ARR 
= 1.28, 95%CI, 1.12-1.46) as compared to women with breast cancer. Men with colorectal cancer 
had a 106% higher risk of newly-diagnosed depression (ARR = 2.06, 95% CI, 1.65-2.58) as 
compared to men with prostate cancer. 
2.6.3 Sex and newly-diagnosed depression 
 This study found a significantly higher percentage of newly-diagnosed depression among 





Tables 4 displays the RR and ARR of newly-diagnosed depression by sex. After controlling for 
all the risk factors and the year at cancer diagnosis, women with colorectal cancer had a 52% 
higher risk of newly-diagnosed depression as compared to men with colorectal cancer (ARR= 
1.52 [95%CI, 1.26-1.83]).  
Cancer stage and newly-diagnosed depression 
This study found that cancer survivors diagnosed at stage II had 22% higher risk of 
newly-diagnosed depression as compared to those diagnosed at stage I (ARR= 1.22 [95%CI, 
1.06-1.40]). Cancer survivors diagnosed at stage III had 41% higher risk of newly-diagnosed 
depression as compared to those diagnosed at stage I (ARR= 1.41 [95%CI, 1.19-1.68]). This 
study also found that cancer survivors diagnosed at stage IV had 63% higher risk of newly-
diagnosed depression as compared to those diagnosed at stage I (ARR= 1.63 [95%CI, 1.31-




This is the first study to date that has evaluated the relationship between cancer types and 
the risk of newly-diagnosed depression after cancer diagnosis among elderly individuals with 
incident breast, colorectal and prostate cancer. In our study, the rate of newly-diagnosed 
depression was highest (5.8%) among women with colorectal cancer and lowest (1.6%) among 
men with prostate cancer. The rate of newly-diagnosed depression among women with breast 
cancer was 3.9% in our study. This rate is higher than the one estimate (2.4%) available from the 
published literature (6). The higher incidence of depression among women with breast cancer in 
our study may be due to differences in observation years as it has been reported that the 





(18). While Danese and colleague used data from 1998 through 2002, the current study utilized 
data from 2007 through 2012 (6).  No other studies have examined the incidence of depression 
among patients with prostate and colorectal cancer. Therefore, the incidence of depression for 
these cancer types found in our study were not compared to estimates from other studies.  
This study found that the risk of newly-diagnosed depression varied by cancer type. 
Women with colorectal cancer had a higher risk of newly-diagnosed depression as compared to 
women with breast cancer, even after adjustments for a comprehensive list of risk factors. 
Similarly, men with colorectal cancer had a higher risk of newly-diagnosed depression as 
compared to men with prostate cancer. These findings were robust in different model 
specifications and they provide new evidence on the variable risk of depression by cancer type. 
As stated in the introduction, it is plausible that poor survival prognosis and late stage at cancer 
diagnosis may have increased the risk of depression among colorectal cancer survivors. For 
example, in the current study, women and men colorectal cancer survivors were more likely to 
be diagnosed at an advanced stage as compared to women with breast cancer and men with 
prostate cancer. In multivariable analyses, advanced stage at cancer diagnosis was associated 
with higher risk of newly-diagnosed depression as compared to early-stage at cancer diagnosis. 
This finding is consistent with prior published studies that documented that advanced stage at 
cancer diagnosis is associated with high risk of depression (6,19). This study also found that 
women with colorectal cancer had 52% higher risk of newly-diagnosed depression as compared 
to men with colorectal cancer. This finding confirmed sex differences in the risk of depression 
which have been documented in the previous literature (18).   





Findings from our study have clinical practice and policy implications. Our findings 
suggest that oncologists and other healthcare providers may need to screen for depression, 
especially individuals with colorectal cancer  and those who are diagnosed with an advanced  
cancer stage. Indeed, the American Society of Clinical Oncology guideline recommends 
screening for depression regardless of cancer types or stage at cancer diagnosis.(20) Cancer is a 
dominant condition and most of the care is usually directed towards treating cancer, therefore, 
such screening is important to diagnose depression before it becomes severe. It is reported that, 
as compared to non-cancer patients, cancer patients who were screened for depression often 
exhibited severe depressive symptoms (21); for these individuals early screening for depression 
is needed. Screening should occur not only in the oncology setting but also in the primary care 
setting, as Medicare provides reimbursement for annual screenings for depression in primary 
care settings (22). Our findings indicate that patients who visited a primary care providers have a 
higher incidence of  depression diagnosis. Therefore, it is important for cancer survivors to 
continue visits to their primary care physicians. A national survey of physicians conducted by the 
Cancer Care Outcomes Research and Surveillance Consortium has shown that PCPs are more 
involved in detection and treatment of depression in cancer patients as compared to oncologists 
(50% vs. 18%) (23). Therefore, coordinated care between oncologists and primary care providers 
is needed so that oncologists can refer cancer patients to primary care providers for depression 
screening.  
Study strengths and limitations 
This study’s findings need to be interpreted in the context of its advantages and 
limitations. One advantage is that this study used linked cancer registry and claims data in which 





is that this study has also controlled for a comprehensive list of factors, including cancer stage 
and cancer treatment, that may affect the risk of newly-diagnosed depression. A third advantage 
is that the availability of cancer diagnosis dates enabled us to identify newly-diagnosed 
depression. This study also has some limitations. As the study population was restricted to fee-
for-service Medicare beneficiaries and those residing in SEER regions, the study findings are not 
generalizable to all Medicare beneficiaries. It is plausible that depression may be under-
recognized and the rate of newly-diagnosed depression may have been underestimated. While 
many variables that may be associated with the risk of newly-diagnosed depression were 
captured, some important variables such as family history of depression, obesity, and physical 
activity were lacking.  
2.8 Conclusion 
 
This study has provided new evidence that there is variation in the risk of newly-
diagnosed depression by cancer type. It identified cancer survivors who are more likely to suffer 
from depression after cancer diagnosis. Healthcare providers of cancer survivors may need to 
screen routinely individuals at high risk for depression, specifically those with colorectal cancer 
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Selected Characteristics of the Study Population by Cancer Types 
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer 
SEER-Medicare database 2007-2012 






Cancer   
  N % N % N % N % chisq sig 
Individual Physical Make-up 
Age in years        3104.2 *** 
 66-69 years 4,768 34.0 1,042 7.4 1,171 8.4 7,026 50.2   
 70-74 years 5,229 33.1 1,389 8.8 1,434 9.1 7,739 49.0   
 75-79 years 4,199 37.2 1,439 12.8 1,100 9.8 4,538 40.2   
 80 years or older 5,382 42.2 2,877 22.6 1,389 10.9 3,099 24.3   
Race         283.1 *** 
 White 16,358 37.7 5,304 12.2 3,986 9.2 17,732 40.9   
 AA 1,627 32.7 719 14.5 374 7.5 2,253 45.3   
 Others 1,593 29.1 724 13.2 734 13.4 2,417 44.2   
Social Support 
Marital Status         8300.9 *** 
 Married  8,126 28.8 2,152 7.6 3,309 11.7 14,663 51.9   
 Never married 1,799 37.4 625 13.0 567 11.8 1,820 37.8   
 Sep/div/wid 8,719 54.1 3,625 22.5 972 6.0 2,800 17.4   
 Unknown 934 20.1 345 7.4 246 5.3 3,119 67.2   
Access to care 
Primary care visits        352.9 *** 
 Quartile 1 (Low) 2,636 33.9 844 10.8 865 11.1 3,440 44.2   
 Quartile 2 1,929 35.2 527 9.6 513 9.4 2,516 45.9   
 Quartile 3 8,242 40.0 2,474 12.0 1,890 9.2 7,986 38.8   
 Quartile 4 (High) 6,771 33.9 2,902 14.5 1,826 9.1 8,460 42.4   
Health behaviors 
Tobacco Use        99.2 *** 
 Yes 514 27.0 213 11.2 244 12.8 931 48.9   
 No 19,064 36.7 6,534 12.6 4,850 9.3 21,471 41.4   
Psychological factors 
Anxiety-PTSD        270.3 *** 
 Yes 1,159 48.1 414 17.2 170 7.0 669 27.7   
 No 18,419 35.8 6,333 12.3 4,924 9.6 21,733 42.3   
 
          
          
          
          
Continued,          






Selected Characteristics of the Study Population by Cancer Types 
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer 
SEER-Medicare database 2007-2012 






Cancer   
  N % N % N % N % chisq sig 
Biological Risk Factors 
Cancer Stage        26141.0 *** 
 Stage 0 3,441 78.8 520 11.9 407 9.3 0 0.0   
 Stage I 8,912 73.4 1,856 15.3 1,331 11.0 39 0.3   
 Stage II 5,157 18.2 2,070 7.3 1,483 5.2 19,638 69.3   
 Stage III 1,453 24.5 1,735 29.2 1,322 22.3 1,431 24.1   
 Stage IV 615 20.3 566 18.7 551 18.2 1,294 42.8   
Cardiovascular         36.4 *** 
 Yes 15,461 36.0 5,552 12.9 4,107 9.6 17,868 41.6   
 No 4,117 38.0 1,195 11.0 987 9.1 4,534 41.9   
Musculoskeletal        1437.7 *** 
 Yes 5,282 47.9 1,884 17.1 726 6.6 3,134 28.4   
 No 14,296 33.4 4,863 11.4 4,368 10.2 19,268 45.0   
Respiratory        97.0 *** 
 Yes 2,126 34.7 945 15.4 699 11.4 2,349 38.4   
 No 17,452 36.6 5,802 12.2 4,395 9.2 20,053 42.0   
Treatment factors 
Chemotherapy         1028.3 *** 
 Yes 3,884 26.6 1,674 11.4 1,601 10.9 7,469 51.1   
 No 15,694 40.0 5,073 12.9 3,493 8.9 14,933 38.1   
Radiation therapy        4610.0 *** 
 Yes 9,193 46.0 600 3.0 686 3.4 9,517 47.6   
 No 10,385 30.7 6,147 18.2 4,408 13.0 12,885 38.1   
Surgery         23164.3 *** 
 Yes 18,193 53.8 5,779 17.1 4,131 12.2 5,723 16.9   
 No 1,385 6.9 968 4.8 963 4.8 16,679 83.4   
Community Resources 
CMHC         5.5  
 Yes 10,030 36.5 3,496 12.7 2,648 9.6 11,332 41.2   
 No 9,548 36.3 3,251 12.4 2,446 9.3 11,070 42.1   
HPSA         57.3 *** 
 No shortage 1,871 36.7 677 13.3 477 9.4 2,075 40.7   
 Whole county 9,693 35.3 3,319 12.1 2,736 10.0 11,700 42.6   









Selected Characteristics of the Study Population by Cancer Types 
Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer 
SEER-Medicare database 2007-2012 






Cancer   
  N % N % N % N % chisq sig 
Geographical Location 
Region         181.4 *** 
 Northeast 3,852 37.7 1,515 14.8 942 9.2 3,919 38.3   
 South 5,003 36.9 1,733 12.8 1,312 9.7 5,516 40.7   
 North-central 2,603 36.8 987 13.9 627 8.9 2,863 40.4   
 West 8,120 35.4 2,512 10.9 2,213 9.6 10,104 44.0   
Metro status        9.2 * 
 Metro  15,947 36.5 5,460 12.5 4,056 9.3 18,196 41.7   
 Non-metro  3,631 35.7 1,287 12.7 1,038 10.2 4,206 41.4   
Cancer diagnosis year       31.901 ** 
 2007 2,876 34.9 1,068 13.0 797 9.7 3,495 42.4   
 2008 3,916 35.2 1,433 12.9 1,110 10.0 4,655 41.9   
 2009 4,091 36.6 1,443 12.9 1,006 9.0 4,627 41.4   
 2010 4,208 37.2 1,372 12.1 1,065 9.4 4,666 41.3   
 2011 4,487 37.4 1,431 11.9 1,116 9.3 4,959 41.3   
            
 
Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate 
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive 
during the observation period.  Asterisks represent significant differences in study population characteristics by 
breast, colorectal and prostate cancer, derived from chi-square statistics. 
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 
 
AA: African American; CMHC: Community Mental Health Center; HH: household; HS: High school; HPSA: health 





















 Number and Percentage of Newly-Diagnosed Depression  by Cancer Types and Treatment 
Characteristics Elderly Fee-for-service Medicare beneficiaries with Incident Breast, 
colorectal, and Prostate Cancer  
SEER-Medicare Database, 2007-2012 
  Depression   No Depression    
  N  % N    % Chisq Sig 
Cancer types      365.7 *** 
 Women Breast Cancer 755 3.9 18,823 96.1   
 Women Colorectal Cancer 394 5.8 6,353 94.2   
 Men Colorectal Cancer 173 3.4 4,921 96.6   
 Men Prostate Cancer 364 1.6 22,038 98.4   
Stage at cancer diagnosis    95.8 *** 
 Stage 0 154 9.1 4,214 8.1   
 Stage I 433 25.7 11,705 22.5   
 Stage II 705 41.8 27,643 53.0   
 Stage III 262 15.5 5,679 10.9   
 Stage IV 132 7.8 2,894 5.6   
Chemotherapy      0.1  
 Yes 454 26.9 14,174 27.2   
 No 1,232 73.1 37,961 72.8   
Radiation therapy     49.5 *** 
 Yes 489 29.0 19,507 37.4   
 No 1,197 71.0 32,628 62.6   
Surgery     110.6 *** 
 Yes 1,265 75.0 32,561 62.5   
 No 421 25.0 19,574 37.5   
        
 
Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate 
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive 
during the observation period.  Asterisks represent significant differences in newly-diagnosed depression by cancer 
types, derived from chi-square tests.  
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 
 







Adjusted Risk Ratios and 95% Confidence Intervals  (CI) of  Cancer Types from Complementary Log-Log  
Regression on Newly-Diagnosed Depression 
 Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and Prostate Cancer 
SEER-Medicare database, 2007-2012 
Model 1: Included the types of cancer without adjustment 
Cancer types  RR 95%CI Sig  RR 95%CI Sig 
 Reference group = Women Breast Cancer   Reference group = Men Prostate Cancer  
 Women Colorectal Cancer 1.53 [ 1.36 ,  1.73] *** Women Breast Cancer 2.29 [ 1.97 ,  2.67] *** 
 Men Colorectal Cancer 0.88 [ 0.74 ,  1.04]  Women Colorectal Cancer  3.10 [ 2.62 ,  3.66] *** 
 Men Prostate Cancer 0.42 [ 0.37 ,  0.47] *** Men Colorectal Cancer 2.12 [ 1.74 ,  2.57] *** 
         
  ARR 95%CI Sig  ARR 95%CI Sig 
Model 2: Adjusted for Individual Physical Make-up and access to care 
 Women Colorectal Cancer 1.49 [ 1.32 ,  1.69] *** Women Breast Cancer 2.17 [ 1.90 ,  2.47] *** 
 Men Colorectal Cancer 0.98 [ 0.83 ,  1.16]  Women Colorectal Cancer  3.23 [ 2.77 ,  3.77] *** 
 Men Prostate Cancer 0.46 [ 0.40 ,  0.53] *** Men Colorectal Cancer 2.12 [ 1.77 ,  2.55] *** 
         
Model 3 Adjusted for cancer type, individual physical make-up and access to care characteristics, health behaviors, and 
biological risk factors 
 Women Colorectal Cancer 1.35 [ 1.19 ,  1.54] *** Women Breast Cancer 2.33 [ 2.00 ,  2.72] *** 
 Men Colorectal Cancer 0.92 [ 0.78 ,  1.10]  Women Colorectal Cancer 3.14 [ 2.66 ,  3.72] *** 
 Men Prostate Cancer 0.44 [ 0.37 ,  0.51] *** Men Colorectal Cancer 2.06 [ 1.70 ,  2.51] *** 
         
Model 4: Adjusted for cancer type, individual physical make-up and access to care characteristics, health behaviors, and 
biological risk factors, treatment factors, community resources, geographical location, and year at cancer diagnosis 
 Women Colorectal Cancer 1.28 [ 1.12 ,  1.46] *** Women Breast Cancer 2.33 [ 1.95 ,  2.78] *** 
 Men Colorectal Cancer 0.88 [ 0.73 ,  1.05]  Women Colorectal Cancer 2.98 [ 2.47 ,  3.60] *** 
 Men Prostate Cancer 0.43 [ 0.36 ,  0.51] *** Men Colorectal Cancer 2.04 [ 1.65 ,  2.51] *** 
         
 
Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate 
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive 
during the observation period.  Asterisks represent significant differences in newly-diagnosed depression by cancer 
types, derived from complementary log-log regression. 
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
 














Table 2.4  
Sex Differences in Newly-Diagnosed Depression Adjusted Risk Ratios and 95% Confidence 
Intervals of Cancer Types from Complementary Log-Log  Regression 
 on Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident  
Breast, colorectal, and Prostate Cancer  
SEER-Medicare Database, 2007-2012 
  Reference group= Men Colorectal Cancer 
 
Model 1 
Adjusted only for cancer types 
Reference Group = Men Colorectal Cancer   
Cancer types  RR 95%CI Sig 
 Women Breast Cancer  1.14 [ 0.96 ,  1.34] 
 Women Colorectal Cancer 1.74 [ 1.46 ,  2.08] *** 
 Men Prostate Cancer  0.47 [ 0.40 ,  0.57] *** 
     
  ARR 95%CI Sig 
Model 2 
Adjusted for cancer types, individual physical make-up and access to care characteristics 
 Women Breast Cancer  1.02 [ 0.86 ,  1.21] 
 Women Colorectal Cancer 1.52 [ 1.27 ,  1.83] *** 
 Men Prostate Cancer  0.47 [ 0.39 ,  0.57] *** 
     
Model 3 
 Adjusted for cancer types, individual physical make-up and access to care characteristics, health 
behaviors, and biological risk factors 
 Women Breast Cancer  1.13 [ 0.95 ,  1.35] 
 Women Colorectal Cancer 1.52 [ 1.27 ,  1.83] *** 
 Men Prostate Cancer  0.48 [ 0.40 ,  0.59] *** 
     
Model 4 
Adjusted for cancer types, individual physical make-up and access to care characteristics, health 
behaviors, and biological risk factors, treatment factors, community resources, geographical location, 
and year of cancer diagnosis 
 Women Breast Cancer  1.14 [ 0.96 ,  1.36] 
 Women Colorectal Cancer 1.46 [ 1.22 ,  1.76] *** 
 Men Prostate Cancer  0.49 [ 0.40 ,  0.61] *** 
     
 
Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate 
cancer who were continuously enrolled in Medicare Part A and B during the observation period and who were alive 
during the observation period.  Asterisks represent significant differences in newly-diagnosed depression by cancer 
types, derived from complementary log-log regression. 
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
 










Appendix 2.1  
Adjusted Risk Ratios (ARR) and 95% Confidence Intervals (CI) from Complementary Log-Log  Regression on 
Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and 
Prostate Cancer SEER-Medicare Database, 2007-2012 
  Model 2  Model 3  Model 4  
  ARR 95%CI Sig ARR 95%CI Sig ARR 95%CI Sig 
Biological Risk Factors 
Cancer types          
 
Women Breast Cancer 
(Ref.)          
 Women colorectal cancer 1.49 [ 1.32 ,  1.69] *** 1.35 [ 1.18 ,  1.53] *** 1.28 [ 1.12 ,  1.46] *** 
 Men colorectal cancer 0.98 [ 0.83 ,  1.16]  0.88 [ 0.74 ,  1.05]  0.84 [ 0.70 ,  1.00]  
 Men Prostate Cancer 0.46 [ 0.40 ,  0.53] *** 0.43 [ 0.37 ,  0.50] *** 0.41 [ 0.34 ,  0.49] *** 
Individual Physical Make-up 
Age           
 66-69 1.25 [ 1.09 ,  1.43] ** 1.27 [ 1.11 ,  1.47] *** 1.31 [ 1.13 ,  1.52] *** 
 70-74 1.05 [ 0.92 ,  1.21]  1.08 [ 0.94 ,  1.24]  1.12 [ 0.97 ,  1.29]  
 75-79 1.08 [ 0.94 ,  1.24]  1.08 [ 0.94 ,  1.25]  1.11 [ 0.96 ,  1.28]  
 >=80 (Ref.)          
Race          
 White (Ref.)          
 African American 0.73 [ 0.61 ,  0.87] *** 0.74 [ 0.62 ,  0.89] ** 0.72 [ 0.59 ,  0.86] *** 
 Hispanic 1.10 [ 0.83 ,  1.46]  1.06 [ 0.80 ,  1.40]  1.03 [ 0.77 ,  1.37]  
 Others 0.52 [ 0.41 ,  0.66] *** 0.56 [ 0.44 ,  0.71] *** 0.55 [ 0.43 ,  0.70] *** 
 Unknown 1.78 [ 0.66 ,  4.79]  2.12 [ 0.80 ,  5.60]  2.11 [ 0.80 ,  5.58]  
Social support 
 Married (Ref.)          
 Never married 1.40 [ 1.19 ,  1.66] *** 1.32 [ 1.11 ,  1.56] ** 1.29 [ 1.09 ,  1.53] ** 
 Sep/div/wid 1.46 [ 1.30 ,  1.63] *** 1.37 [ 1.22 ,  1.54] *** 1.35 [ 1.20 ,  1.52] *** 
 Unknown 1.02 [ 0.83 ,  1.26]  1.02 [ 0.82 ,  1.26]  1.00 [ 0.81 ,  1.23]  
Access to care 
Median HH income         
 Quartile 1 (Low) 1.02 [ 0.83 ,  1.25]  0.99 [ 0.81 ,  1.22]  1.04 [ 0.83 ,  1.30]  
 Quartile 2 0.92 [ 0.77 ,  1.10]  0.90 [ 0.75 ,  1.08]  0.94 [ 0.78 ,  1.14]  
 Quartile 3 0.94 [ 0.80 ,  1.10]  0.93 [ 0.79 ,  1.09]  0.95 [ 0.80 ,  1.12]  
 Quartile 4 (High)         
% LT HS education         
 Quartile 1 (Low) 0.79 [ 0.64 ,  0.97] * 0.99 [ 0.81 ,  1.22]  0.83 [ 0.67 ,  1.03]  
 Quartile 2 0.84 [ 0.71 ,  1.00]  0.90 [ 0.75 ,  1.08]  0.89 [ 0.74 ,  1.07]  
 Quartile 3 0.84 [ 0.72 ,  0.98] * 0.93 [ 0.79 ,  1.09]  0.87 [ 0.75 ,  1.02]  
 Quartile 4 (High)         
Primary care visits         
 Quartile 1 (Low)          
 Quartile 2 1.02 [ 0.83 ,  1.27]  1.02 [ 0.83 ,  1.27]  1.03 [ 0.83 ,  1.27]  
 Quartile 3 1.01 [ 0.86 ,  1.19]  1.00 [ 0.85 ,  1.18]  0.98 [ 0.83 ,  1.15]  
 Quartile 4 (High) 1.49 [ 1.28 ,  1.75] *** 1.27 [ 1.07 ,  1.50] ** 1.27 [ 1.08 ,  1.50] ** 
Health behaviors 
Tobacco Use          
 Yes    1.22 [ 0.97 ,  1.52]  1.28 [ 1.03 ,  1.60] * 
 No (Ref.)          
Psychological factors 
Anxiety-PTSD          
 Yes    3.66 [ 3.21 ,  4.17] *** 3.72 [ 3.26 ,  4.24] *** 
 No (Ref.)          
           





Appendix 2.1  
Adjusted Risk Ratios (ARR) and 95% Confidence Intervals (CI) from Complementary Log-Log  Regression on 
Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and 
Prostate Cancer SEER-Medicare Database, 2007-2012 
  Model 2  Model 3  Model 4  
  ARR 95%CI Sig ARR 95%CI Sig ARR 95%CI Sig 
           
Biological risk factors 
Cardiovascular          
 Yes    1.00 [ 0.87 ,  1.15]  1.00 [ 0.87 ,  1.15]  
 No (Ref.)          
Musculoskeletal disease         
 Yes    1.19 [ 1.07 ,  1.34] ** 1.19 [ 1.07 ,  1.33] ** 
 No (Ref.)          
Respiratory          
 Yes    1.11 [ 0.96 ,  1.27]  1.10 [ 0.96 ,  1.27]  
 No (Ref.)          
Stage at cancer diagnosis         
 Stage 0    0.98 [ 0.82 ,  1.18] *** 0.98 [ 0.82 ,  1.18] *** 
 Stage I (Ref.)          
 Stage II    1.22 [  1.06,  1.40] **  1.21 [ 1.06 ,  1.40] ** 
 Stage III    1.41 [ 1.19 ,  1.68] *** 1.39 [ 1.17 ,  1.68] *** 
 Stage IV     1.63 [ 1.31,  2.03] *** 1.61 [ 1.30,  2.00] *** 
Treatment factors 
Chemotherapy          
 Yes       1.01 [ 0.90 ,  1.14]  
 No (Ref.)          
Radiation therapy          
 Yes       0.83 [ 0.74 ,  0.93] ** 
 No (Ref.)          
Continued          
Surgery          
 Yes       0.97 [ 0.84 ,  1.12]  
 No (Ref.)          
Community Resources  
Community mental health center        
 Yes       1.11 [ 0.99 ,  1.24]  
 No (Ref.)          
HPSA- Mental Health Care        
 Whole county       0.93 [ 0.77 ,  1.12]  
 Part county       0.94 [ 0.79 ,  1.12]  
 No shortage (Ref.)         
Geographical Location  
Region          
 Northeast       0.96 [ 0.82 ,  1.12]  
 South       1.00 [ 0.88 ,  1.15]  
 North-central       0.98 [ 0.83 ,  1.16]  
 West (Ref.)          
Metro status          
 Metro county       1.03 [ 0.89 ,  1.20]  
 Non metro county (Ref.)        
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Adjusted Risk Ratios (ARR) and 95% Confidence Intervals (CI) from Complementary Log-Log  Regression on 
Newly-Diagnosed Depression Elderly Fee-for-service Medicare beneficiaries with Incident Breast, colorectal, and 
Prostate Cancer SEER-Medicare Database, 2007-2012 
  Model 2  Model 3  Model 4  
  ARR 95%CI Sig ARR 95%CI Sig ARR 95%CI Sig 
         
Year at cancer diagnosis         
 2007       0.98 [ 0.83 ,  1.15]  
 2008       1.14 [ 0.99 ,  1.32]  
 2009       1.05 [ 0.91 ,  1.22]  
 2010       1.06 [ 0.92 ,  1.23]  
 2011 (Ref.)          
 
Note: Based on 53,821 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate cancer who 
were continuously enrolled in Medicare Part A and B during the observation period and who were alive during the observation 
period.  Asterisks represent significant differences in newly-diagnosed depression by cancer types, derived from complementary 
log-log regression. 
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
Model 1: Adjusted for cancer types. Model 2: Adjusted for cancer types and individual physical make-up; Model 3: Adjusted for 
cancer types, access to care, health behaviors, and biological risk factors. Model 4: adjusted cancer types, access to care, health 
behaviors, biological risk factors, treatment factors, community resources, geographical location, and year at cancer diagnosis. 
Asterisks (*) represent significant differences based on complementary log log regressions with women cancer types as the 
reference groups   
***P< .001; **.001 ≤ P < .01; *.01 ≤ P < .05.  
AA: African American; ARR: Adjusted Risk Ratio; CMHC: Community Mental Health Center; HH: household; HS: High 
school; HPSA: health professional shortage area; LT: less than; RR: Risk Ratio; Ref: Reference Group; SEER: Surveillance 



































Appendix 2.2 Study Cohort Development Flow Diagram for Study Population of Elderly Medicare 




























Reason for exclusion:  
 Not one primary cancer (Breast 
n=39,257, Colorectal n=34,683, 
Prostate  n=34,738) 
 Diagnosed at autopsy or death cert. 
(Breast  n=854, Colorectal n=1,061, 
Prostate  n=1,545) 
 Not incident cases (Breast n=33,418, 
Colorectal n=30,827, Prostate  
 Cancer diagnosed identified using Siterwho 1- -10 codes  
          Breast N = 392,684, Colorectal N= 291,491, Prostate N= 461,994 
 Diagnosed with cancer from April 2007 to Dec 2011 
         Breast N = 169,955, Colorectal N= 125,261, Prostate N= 205,505 
 
 Diagnosed with cancer from April 2007 to Dec 2011 
 Primary cancer only in the patient’s lifetime (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases 
Breast N = 129,206, Colorectal N= 89,272, Prostate N= 168,783 
 
 Elderly with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases, >=66,  alive  
Breast N = 73,496, Colorectal N= 45,571, Prostate N= 107,585 
 
 Diagnosed with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate , 
Incident cases, >=66,   alive  
 Fee-for-service continuous enrollment and part D enrollment 
3m before cancer dx 
Breast N = 23,632, Colorectal N= 13,988, Prostate N= 24,726 
 
Reasons for exclusion: 
 <66 years old (Breast  n=47,290, 
Colorectal n=23,744, Prostate  
n=56,295) 
 Unknown stage of cancer (Breast  
Colorectal  n=6,614, Prostate  
n=4,619, n=10,185) 
 Death (Breast  n=4,063, Colorectal  
 
Reasons for exclusion: 
 HMO enrollment (Breast  n=23,647, Prostate  
n=14,362, n=30,104) 
 No Continuous enroll in Part A & B (Breast  
n=4,840, Colorectal  n=3,545, Prostate  
n=10,677) 
 No Continuous enroll in Part D (Breast  
n=21,377, Colorectal  n=13,676, Prostate  
n=32,954) 
 
Reasons for exclusion: 
 Not depression free before cancer dx  (Breast 
n=3,925, Colorectal  n=2,060, Prostate 
n=2,252) 
 Final Analytical Cohort 
 
 Diagnosed with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases,  >=66,   alive,  Fee-for-service continuous 
enrollment and part D enrollment 3m before cancer dx 
 Depression free  
Breast N = 19,578, Colorectal N= 11,841, Prostate N= 22,402 
 







Depression Treatment among Elderly Medicare Beneficiaries with Incident 




Objective. Depression treatment can improve the health outcomes of elderly cancer survivors. 
However, there is a paucity of studies on the extent to which newly-diagnosed depression is 
treated among elderly cancer survivors. Therefore, the primary objective of this study is to 
estimate the rates of treatment for newly-diagnosed depression and to identify the factors 
affecting depression treatment among elderly individuals with incident cancer. 
Methods. This study adopted a retrospective cohort study design with data from the linked 
Surveillance, Epidemiology and End Results (SEER) and Medicare database. Elderly individuals 
(> 66 years) with incident breast, colorectal or prostate cancer and newly diagnosed depression 
(N= 1,673) were followed for six months after depression diagnosis date to identify depression 
treatment. Depression treatment was categorized into four mutually exclusive categories: 1) 
treatment with only antidepressants; 2) treatment with only psychotherapy; 3) combined 
treatment with both antidepressants and psychotherapy; and 4) no depression treatment. Chi-
square tests and multinomial logistic regressions were used to analyze the factors (predisposing, 
enabling and need factors as well as the external environment) associated with depression 
treatment.  
Results. In our study population, 45.7% received only antidepressants, 8.8% received only 
psychotherapy, 18.4% received combined therapy and 27.1% received no treatment for 
depression. This study found that cancer survivors who received cancer treatment after 
depression diagnosis were less likely to receive psychotherapy only (Adjusted Odds Ratio 





compared to those who received cancer treatment before depression diagnosis. This study also 
found that residents living in counties with a higher percentage of psychologists were more likely 
to receive psychotherapy only (Adjusted Odds Ratio (AOR) = 2.17 [95%CI, 1.20-3.90]), or 
combined therapy (AOR = 1.55 [95%CI, 1.03-2.33]). Other factors associated with depression 
treatment were: race, the number of primary care physician visits, the presence of other chronic 
conditions, and anxiety.  
Conclusion. The study findings indicate that two-third of cancer survivors received some 
depression treatment in the first six months after depression diagnosis. The majority of cancer 
survivors received antidepressants only to treat newly-diagnosed depression. Certain 
predisposing, enabling and need factors as well as external environmental factors were 
associated with depression treatment.   
Implications.  Despite the clinical guidelines’ recommendations for treating depression among 
cancer survivors, one-fourth of cancer survivors do not receive any depression treatment. Future 
research needs to investigate whether these individuals receive alternative therapies for newly-













3.2 Introduction  
 
Depression is a treatable and highly prevalent mental health condition among cancer 
survivors (1,2). Relief from clinical depression can be achieved with either pharmacotherapy or 
psychotherapy or a combination of pharmacotherapy and psychotherapy (3). Pharmacotherapy 
typically consists of antidepressants such as selective serotonin reuptake inhibitors (SSRIs), 
selective norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), 
monoamine oxidase inhibitors (MAOIs) and others (mirtazapine, bupropion) (3). Different forms 
of psychotherapy are used to treat depression such as cognitive-behavioral therapy and problem-
solving therapy (3).  
The efficacy of antidepressants for treating depression among older adults (age > 65 
years) in the general population (4,5) and cancer survivors (6-12) has been evaluated by many 
randomized clinical trials (RCTs). These trials have not yet established the efficacy of 
antidepressants in treating depression among older adults. For example, a meta-analysis of six 
double-blind RCTs involving patients aged 65 and older found no statistically significant 
differences between the treatment with antidepressants and the placebo groups (Relative Risk = 
1.13; 95% CI: 0.93–1.37, p = 0.265) (4,5). Among cancer survivors, there is mixed evidence 
from seven RCTs on the efficacy of antidepressants in treating cancer patients with depression. 
In five RCTs, cancer patients who used antidepressants were more likely to achieve a therapeutic 
response as compared to the placebo (6-10). However, in two RCTs antidepressants were not 
found to be efficacious (11,12). The efficacy of psychotherapy alone in treating depression has 
been established efficacy for elderly individuals in the general population (13) and among adults 





established efficacy in reducing depressive symptoms, in some RCTs, among the elderly in the 
general population (19,20) but not among adults with cancer (21).  
As various depression treatment modalities have been found to be efficacious among 
older adults, clinical practice guidelines have recommended depression treatment for cancer 
patients (22-24). These guidelines do not recommend antidepressants over psychotherapy alone 
or in combination with antidepressants, nor do they recommend one antidepressant over another. 
Although depression treatment is recommended to reduce the depressive symptoms for cancer 
survivors, it is not known how depression is treated in the real-world clinical practice settings 
among elderly with cancer. Research on treatment of newly-diagnosed depression among cancer 
survivors has not received much attention. In the United States, only two cross-sectional studies 
examined depression treatment among cancer survivors seeking care in real-world clinical-
practice settings (25,26). Of these two studies, one study focused on elderly (age > 65 years) 
Medicare beneficiaries with cancer using data between 2000 and 2005 (25) and another study 
used MEPS from multiple years 2006-2008 among adults with both cancer and depression (26). 
Findings from these studies revealed that an estimated 76% and 84% of elderly cancer survivors 
received any depression treatment. These studies were among cancer survivors with prevalent 
depression and any type of cancer. These studies did not include cancer-related clinical factors 
such as stage at cancer diagnosis and cancer treatment, which might affect depression treatment. 
Furthermore, these studies used self-reported data on either antidepressant use or depression 
diagnosis.  
There are no studies that examined the treatment of depression among cancer survivors 
with newly-diagnosed depression. In addition, no studies distinguish depression treatment among 





objective of the current study was to fill the knowledge gap in estimating depression treatment 
and the factors associated with depression treatment among breast, colorectal or prostate cancer 
survivors with newly-diagnosed depression. This study used a retrospective cohort design with 
data from clinical care encounters and prescription drug claims to analyze depression treatment 
among cancer survivors with newly-diagnosed depression. These cancers were selected due to 
their high prevalence; they are projected to be the most common types of cancer by 2024, with 
breast cancer among women expected to be 41%, prostate cancer among men to be 45%, and 
colorectal cancer among men and women to be 8%.  
3.3 Conceptual framework  
 
The expanded behavioral model on healthcare utilization, the Andersen Behavioral 
Model, was used to guide the selection of factors that may affect depression treatment (27). 
According to this model, depression treatment (i.e. health services utilization) is a function of: 1) 
an individual’s predisposition to utilize the services – predisposing factors; 2) factors which 
enable individuals to use healthcare services – enabling factors; 3) an individual’s level of need – 
need factors; 4) personal health practices, and 5) the external environment.  
3.4 Methods 
 
3.4.1 Study Design 
This study utilized retrospective cohort study design with baseline and follow-up periods. 
The first observed date of depression diagnosis after cancer diagnosis was considered as an index 
date. The baseline period was defined as 12 months before this index date and the follow-up 





3.4.2 Data Sources 
 The current study linked data from several sources including the SEER-Medicare linked 
database and the AHRF files. The detailed description of the data sources are provided in 
Chapter 1. 
3.4.3 Study population 
Identification of Cancer Survivors 
The study population composed of elderly cancer survivors (age > 66 years) who were 
diagnosed with primary only incident breast, colorectal or prostate cancer and newly-diagnosed 
depression between 2007 and 2011. Cancer types (breast, colorectal or prostate cancer) was 
identified using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-
3) histology codes and the primary site variable.  
Cancer Survivors with newly-diagnosed depression 
This study identified cancer survivors with newly-diagnosed depression based on the 
National Committee on Quality Assurance (NCQA) criteria (30). To accomplish this, a 
depression-free cancer cohort with incident cancer diagnosis between April 2007 and December 
2011 was first established. To identify newly-diagnosed depression after cancer diagnosis, only 
those who were diagnosed with depression after cancer diagnosis and did not have any 
antidepressant use 90 days prior to depression diagnosis were included. This study used a 
validated algorithm developed by the Centers for Medicare and Medicaid Services (CMS) 
Chronic Conditions Data Warehouse (CCW) to identify depression (31) using the International 
Classifications of Diseases – 9th edition, Clinical Modification (ICD-9-CM) Codes ( 296.2, 
296.3, 298.0, 300.4, 309.1, and 311.0). These codes are widely used in the literature to identify 






Inclusion/exclusion criteria  
This study required that all individuals have continuous enrollment in Medicare part A, B 
and no enrollment in managed care plans during the baseline and follow-up periods. This study 
also required that individuals have continuous enrollment in Medicare part D six months after 
depression diagnosis to identify depression treatment in the follow-up period. This study 
excluded individuals with unknown cancer stage at diagnosis, those diagnosed through autopsy 
or death certificate, or those who died during the follow-up period. Appendix 1.1 demonstrates 
the analytical population selection process.  The final study population consisted of 1,673 elderly 
Medicare beneficiaries with newly-diagnosed depression and incident breast, colorectal or 
prostate cancer.  
3.4.4 Dependent Variable: Depression Treatment  
This study identified depression treatment during the first six months after depression 
diagnosis. Antidepressant use was derived from Medicare Part D claims using the National Drug 
Codes (NDC) and generic names. Antidepressants included SSRIs, SNRIs, TCAs, MAOIs and 
others (mirtazapine, bupropion). Any cancer survivors with at least one prescription for 
antidepressants was considered as using antidepressants. Psychotherapy visits were derived from 
Medicare outpatient claims using the Current Procedural Terminology (CPT) codes. Any cancer 
survivor with at least one psychotherapy visit was considered as receiving psychotherapy.   
Based on antidepressant prescriptions and psychotherapy visits, depression treatment was 
categorized into four mutually exclusive categories: (1) treatment with antidepressants only: 
individuals received, at least, one prescription of antidepressants and no psychotherapy visit; (2) 
treatment with psychotherapy only: individuals had, at least, one psychotherapy office visit and 





received, at least, one prescription for antidepressants with at least one psychotherapy visit; (4) 
no treatment: individuals received no antidepressants and no psychotherapy.  
3.4.5 Independent Variables 
Predisposing factors included age in years at cancer diagnosis (66-69, 70-74, 75-79, 
>=80) and race (White, African American, and others). Enabling factors consisted of marital 
status (married, divorced/separated/widowed, and never married); number of visits to primary 
care physicians (PCP) by patients (measured in quartiles); cancer types (women with breast 
cancer, women with colorectal cancer, men with colorectal cancer, men with prostate cancer); 
stage at cancer diagnosis (categorized using American Joint Committee on Cancer (AJCC) 
grouped staging (stage 0/I, stage II, and stage III, stage IV) and cancer treatment with 
chemotherapy, radiation therapy, radiation therapy or surgery. As cancer is often considered a 
dominant condition and cancer treatment after depression diagnosis may compete with 
depression care, cancer treatment was cateorized into three groups:1) cancer treatment before 
depression diagnosis; 2) cancer treatment at or after depression diagnosis, and 3) no cancer 
treatment. Need factors composed of chronic conditions, which were selected, based on the 
Multiple Chronic Conditions working group framework (33). The following chronic conditions 
were used: Alzheimer's disease and related disorders (ADRD); anxiety; cardiovascular (diabetes, 
heart disease (cardiac arrythmia, coronary heart disease, congestive heart faliure), 
hyperlipidemia, hypertension, and stroke); musculoskeletal (arthritis, and osteoporosis) and 
respiratory conditions (asthma and chronic obstructive pulmonary disorder). This study 
identified these conditions based on a validated algorithm developed by the CMS Chronic 
Conditions Data Warehouse (31); according to this algorithm, individuals had, at least, one 
inpatient visit or two outpatient visits during the baseline period. External Environment factors 





North-central, and West). This study also controlled for year of cancer diagnosis by grouping the 
years into two groups: 1) 2007-2009, the period when FDA issued a black box warning due to 
the risk of suicides with antidepressants use (34,35) and 2) 2010-2011, the period when 
published articles reported the association between antidepressants and the risk of new-onset 
diabetes (36). This study did not use metro status because it was highly correlated with the 
county-level percentage of psychologists. 
 
3.5 Statistical Analysis 
 
This study used Chi-square tests and multinomial logistic regressions to examine the 
unadjusted differences in subgroups by depression treatment categories. This study used 
multivariable multinomial logistic regressions to examine the adjusted association between the 
independent variables and depression treatment categories. In these regressions, predisposing, 
enabling, need, and external environment factors were included.  In all these models, the 
reference group for the dependent variable was “no depression treatment”.  All statistical 
analyses were carried out in SAS 9.4 (SAS Institute Inc., Cary, NC).   
3.6 Results  
 
3.6.1 Characteristics of the study population 
  The study population consisted of 1,673 elderly fee-for-service Medicare beneficiaries 
with incident breast, colorectal or prostate cancer who had newly-diagnosed depression after 
cancer diagnosis. In this study population, 44.9% were women with breast cancer; 22.8% were 
women with colorectal cancer; 10.1% were men with colorectal cancer, and 22.2% were men 
with prostate cancer. This study found that 35.0% were diagnosed with early stage cancers (stage 
0/I) and 7.1% diagnosed at an advanced stage (stage IV); 68.0% received cancer treatment before 





10.6% did not receive cancer treatment. The description of the study population is presented in 
Table 1. 
Tables 2 and 3 display the unadjusted associations between predisposing, enabling and 
need factors, and external environment and depression treatment categories. Among elderly 
cancer survivors with newly-diagnosed depression, This study found that 27.1% did not receive 
any depression treatment; 45.7% received antidepressants only; 8.8% received psychotherapy 
only, and 18.4% received both antidepressants and psychotherapy. There was a significant 
difference in antidepressant use only by predisposing characteristics (race). For example, a 
significantly lower percentage of African American (odds ratio (OR) = 0.49, 95% Confidence 
interval (CI) = 0.31, 0.77) used antidepressants only as compared to whites (28.3% versus 
47.9%); similarly, a lower percentage of other racial minorities (odds ratio (OR) = 0.54, 95% 
(CI) = 0.36, 0.82) used antidepressants only as compared to whites (41.5 versus 47.9%).   
With regard to the use of psychotherapy only, This study found  significant differences in 
psychotherapy use by enabling factors (marital status, PCP visits, cancer treatment), need factors 
(ADRD, anxiety, respiratory conditions), and external environmental characteristics (county-
level percentage of psychologists and region of residence). For example, a significantly lower 
percentage of individuals who received cancer treatment after depression diagnosis (OR = 0.40, 
95% (CI) = 0.23, 0.70) used psychotherapy as compared to those who received cancer treatment 
before depression diagnosis (4.7% versus 9.3%). Individuals with ADRD had a higher use of 
psychotherapy (OR = 3.27, 95% (CI) = 1.93, 5.56) as compared to those without ADRD (15.1% 
versus 7.9%). 
 This study found significant group differences in the use of combination of 





cancer treatment, and the number of PCP visits), need factors (ADRD, cardiovascular), and 
external environment (county-level number of psychologists and region of residence). For 
example, other racial minorities were less likely to receive combination of antidepressant and 
psychotherapy (OR = 0.41, 95% (CI) = 0.23, 0.74) as compared to whites (11.9% versus 18.1%). 
Individuals with a higher number of PCP visits had higher use of combined 
antidepressant/psychotherapy (OR = 1.03, 95% (CI) = 1.01, 1.05). 
Table 4 presents the adjusted odds ratios (AOR) and 95% CIs from multinomial logistic 
regressions of depression treatment categories.  In these regressions, “no depression treatment” 
was used as the reference group of the dependent variable. The results were generally consistent 
with the unadjusted analyses. This study found significant associations between a predisposing 
factor (race) and only antidepressants use. African Americans were less likely to receive 
antidepressants only as compared to White (AOR = 0.44, 95% (CI) = 0.27, 0.70). This study also 
found a significant association between psychotherapy use and enabling factors (marital status, 
PCP visits, and cancer treatment), need factors (ADRD, anxiety, cardiovascular, and respiratory 
conditions), and external environment (county-level percentage of psychologists, region of 
residence). For example, Individuals with higher number of PCP visits were more likely to use 
psychotherapy (AOR = 1.02, 95% (CI) = 1.00, 1.04). Individuals who received cancer treatment 
after depression diagnosis were less likely to use psychotherapy as compared to those who 
received cancer treatment before depression diagnosis (AOR = 0.40, 95% (CI) = 0.22, 0.72). 
With regard to combined antidepressants/psychotherapy, this study found a significant 
association between combined antidepressants/psychotherapy use and predisposing factor (race), 
enabling factors (PCP visits, cancer treatment), need factors (ADRD) and external environment 





counties with a higher percentage of psychologists were more likely to receive combined 
antidepressants/psychotherapy (AOR = 1.05 [95%CI, 1.00-1.09]). AOR and 95% CI for other 
independent variables are presented in Table 4.  
Of particular interest was the cancer types (Appendix 1.2). This study found that there 
were not significant differences in depression treatment categories between women with 
colorectal cancer as compared to women with women with breast cancer (AOR = 0.93 [95%CI, 
0.67-1.29]); and between men with colorectal cancer as compared to men with prostate cancer 
(AOR = 0.79 [95%CI, 0.48-1.30]).  
3.7 Discussion 
 
In this study, the rates of depression treatment and the factors associated with depression 
treatment for newly-diagnosed depression were estimated among elderly cancer survivors with 
incident breast, colorectal or prostate cancer. In our study population, one in four cancer 
survivors did not receive either antidepressants or psychotherapy for depression. This finding is 
consistent with the one published study depression treatment rate among elderly Medicare 
beneficiaries with cancer (25). Less than 50% of cancer survivors were treated with 
antidepressants only and 27.2% used psychotherapy with or without antidepressants. The 
percentage of antidepressant use is somewhat lower, and the psychotherapy use is higher than the 
estimated rates reported in one published study of Medicare beneficiaries with cancer (25). The 
differences between our study and the published study could be due to differences in the study 
designs (retrospective cross-sectional versus retrospective cohort), measurement of 
antidepressants (self-report versus prescription claims), and identification of depression 





This study also found that only one predisposing factor (race) was associated with the use 
of “antidepressants only.” African Americans and other racial minorities were less likely to use 
antidepressants only as compared to whites. Such racial disparities have been documented 
among elderly Medicare beneficiaries with cancer (25) as well as in the elderly population. Some 
studies have attributed the racial disparities in antidepressant use to cultural factors.  For 
example, it has been documented that African Americans and other racial minorities were less 
likely to accept antidepressants medications as compared to whites (37). A meta-analysis of 
cultural mistrust and mental health services for African Americans suggested a significant 
association between cultural mistrust with mental health services use (38). 
Psychotherapy only or combined use of antidepressants and psychotherapy were 
associated with many factors (enabling, need, and external environment factors). Regarding 
enabling factors, cancer survivors with a higher number of PCP visits were more likely to receive 
psychotherapy and a combination of antidepressants and psychotherapy as compared to those 
with a lower number of PCP visits. This finding suggests that PCP visits may play an important 
role in referring cancer survivors to mental healthcare providers for psychotherapy treatment. A 
national survey of physicians conducted by the Cancer Care Outcomes Research and 
Surveillance Consortium has shown that PCPs are more involved in detection and treatment of 
depression in cancer survivors as compared to oncologists (50% vs. 18%) (39).  
As expected, This study found that those who had initiated cancer treatment after 
depression diagnosis were less likely to receive psychotherapy as compared to those who had 
initiated cancer treatment before depression diagnosis. As psychotherapy sessions involve face-
to-face visits to the mental health providers, cancer survivors may not be able to receive 





support the theory of  competing demands for care, which suggests that cancer is a dominant 
condition and may “eclipse the management of other health conditions.” (40). 
Further, This study found that many co-existing chronic conditions were associated with  
depression treatment. Cancer survivors with respiratory conditions were more likely to receive 
psychotherapy treatment as compared to those without respiratory conditions. This is not 
surprising because psychotherapy is a standard part of the rehabilitation therapy regimen, which 
is used to treat respiratory conditions such as asthma and COPD (41,42). This study also found 
that individuals with ADRD were more likely to receive psychotherapy and a combination of 
antidepressants and psychotherapy as compared to those without ADRD. Cognitive therapy and 
other psychotherapies are some treatment modalities that are used to improve dementia 
symptoms (43). Further, the presence of cardiovascular conditions and anxiety were negatively 
associated with depression treatment. For example, those with cardiovascular conditions were 
less likely to use psychotherapy only as compared to those without cardiovascular conditions. 
While the reasons for this are not known, the lack of robust evidence of depression treatment on 
cardiac outcomes from RCTs (44,45) may discourage physicians from recommending treatment 
for depression. For example, one of the RCTs, which used psychotherapy as the main modality 
of treatment for individuals with depression and heart disease, found no significant differences in 
cardiac outcomes (44). As none of the trials have shown improvement in cardiac outcomes, there 
have been calls for more trials to establish the efficacy of depression treatment on chronic care 
outcomes (46). This study also found that those with pre-existing anxiety were less likely to 
receive treatment as compared to those without anxiety. However, existing studies have shown 





beneficiaries. Thus, the difference in findings could be attributed to the measurement period in 
which anxiety was identified.  
External environmental characteristics were also associated with depression treatment 
categories. This study found that the supply of mental health services was associated with 
psychotherapy use. For example, This study observed that a higher percentage of psychologists 
in a county was significantly associated with psychotherapy use and with a combination of 
antidepressants and psychotherapy use. This is also consistent with the published literature, 
which found that the availability of psychotherapy providers influences psychotherapy use (47).  
This study has filled a knowledge gap by estimating the rates and identifing the factors 
associated with depression treatment categories among those with newly-diagnosed depression 
and incident breast, colorectal or prostate cancer. Our study findings indicate that racial 
disparities in depression treatment persist, competing demands may impede depression care and 
that the availability of psychologists may influence receipt of psychotherapy among cancer 
survivors. The current study made unique contributions to the nascent literature on depression 
care among cancer survivors.  It has to be noted that once diagnosed with depression, neither 
type of cancer nor stage of cancer were associated with depression treatment, suggesting that 
detecting depression and diagnosing depression is critical to depression management among 
cancer survivors.  
Strengths and limitations 
This study’s findings need to be interpreted in the context of its advantages and 
limitations. One advantage is that this study used linked cancer registry and claims data in which 
a large cohort of cancer survivors were followed six months to identify their depression 





comprehensive list of factors including the county-level percentage of psychologists and clinical 
factors such as cancer stage and cancer treatment that may affect the rates of depression 
treatment. A third advantage is that this study used Medicare part D to identify antidepressant 
treatment rates. This study also has some limitations. As the study population was restricted to 
fee-for-service Medicare beneficiaries, those residing in SEER regions and those who had 
Medicare part D coverage the study findings are not generalizable to all Medicare beneficiaries. 
Although other effective treatments for depression exist such as electroconvulsive therapy, this 
study focused on antidepressants and psychotherapy because they are the most commonly used 
depression treatment. While this study captured many variables that may be associated with the 
rates of depression treatment, some important variables such patient preferences were lacking. In 
addition, the reasons for no depression treatment was not explored in this study. This study can 
speculate that some elderly with cancer may not receive depression treatment because of 
competing demands of healthcare management and the prioritization of treatment of cancer. 
Also, providers may not prescribe antidepressants for treating depression due to the lack of 




     Even with a successful diagnosis of depression in the oncology setting, a treatment gap 
exists. One-fourth of cancer survivors with newly-diagnosed depression did not receive any 
depression treatment. Therefore, greater effort is needed to ensure that cancer survivors are 
receiving depression treatment, especially for cancer survivors who initiated cancer treatment 
after depression diagnosis, as competing demands can impede depression care. Depression care 





increase the supply of mental health services. Also, reducing racial disparities is important to 
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Description of the Study Population Elderly Fee-for-service Medicare 
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed 
Depression, 
SEER-Medicare Database, 2007-2012 
  N % 
Total 1,673 100.0 
Predisposing factors 
Age in years   
 66-69 434 25.9 
 70-74 430 25.7 
 75-79 342 20.4 
 >=80 467 27.9 
Race   
 White 1,393 83.3 
 AA 145 8.7 
 Others 135 8.1 
Enabling factors 
Marital Status   
 Married  649 38.8 
 Never married 177 10.6 
 Sep/div/wid/Unkn 847 50.6 
    
Primary care visits (mean (SD))                10.18 (10.08) 
    
Cancer type   
 Breast 752 44.9 
 Women colorectal 381 22.8 
 Men colorectal 169 10.1 
 Prostate 371 22.2 
Cancer Stage   
 Stage 0-I 586 35.0 
 Stage II 720 43.0 
 Stage III 249 14.9 
 Stage IV 118 7.1 
Cancer treatment  
 Before dep. Dx 1,137 68.0 
 After dep. Dx  358 21.4 
 No treatment  178 10.6 
    
    






Description of the Study Population Elderly Fee-for-service Medicare 
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed 
Depression, 
SEER-Medicare Database, 2007-2012 
  N % 
Need factors   
Cardiovascular  
 Yes 1,469 90.8 
 No 148 9.2 
Musculoskeletal  
 Yes 543 33.6 
 No 1,074 66.4 
Respiratory   
 Yes 379 23.4 
 No 1,238 76.6 
Dementia   
 Yes 219 13.1 
 No 1,454 86.9 
Anxiety   
 Yes 437 26.1 
 No 1,236 73.9 
External Environment 
    
% Psychologists (mean (SD))               2.37 (4.21) 
    
Region   
 Northeast 323 19.3 
 south 457 27.3 
 North-central 212 12.7 
 West 681 40.7 
Cancer diagnosis year 
 2007-2009 954 57.0 
 2010-2012 719 43.0 
 
Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal and prostate 
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during  
the observation period and Part D during the follow-up period and who were alive during the observation period.   
 
AA: African American; ADRD: Alzheimer's disease and related disorders; dep: Depression; dx: diagnosis; SEER: 














Description of the Study Population by Depression Treatment Categories 
Elderly Fee-for-service Medicare beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-
diagnosed Depression 
SEER-Medicare Database, 2007-2012 
  Antidepressants Psychotherapy Combined No    
  Only  Only  ADs/Psych Treatment   
  N % N % N % N % chisq sig 
All 764 45.7 148 8.8 308 18.4 453 27.1   
Predisposing factors 
Age in years         8.6  
 66-69 208 47.9 39 9.0 82 18.9 105 24.2   
 70-74 199 46.3 36 8.4 71 16.5 124 28.8   
 75-79 158 46.2 23 6.7 63 18.4 98 28.7   
 >=80 199 42.6 50 10.7 92 19.7 126 27.0   
Race         38.8 *** 
 White 667 47.9 115 8.3 252 18.1 359 25.8   
 AA 41 28.3 23 15.9 40 27.6 41 28.3   
 Others 56 41.5 13 7.4 16 11.9 53 39.3   
Enabling factors 
Marital Status          28.7 *** 
 Married  305 47.0 41 6.3 112 17.3 191 29.4   
 Never married 64 36.2 26 14.7 49 27.7 38 21.5   
 Sep/div/wid/Unkn 395 46.6 81 9.6 147 17.4 224 26.4   
            
Primary care visits 
(mean (SD)) 9.23 (9.06) 13.07 (13.83) 12.27 ( 11.75)  9.41(8.58)  *** 
            
Cancer type         12.4  
 Breast 369 49.1 58 7.7 130 17.3 195 25.9   
 
Women 
colorectal 165 43.3 40 10.5 71 18.6 105 27.6   
 Men colorectal 67 39.6 22 13.0 31 18.3 49 29.0   
 Prostate 163 43.9 28 7.5 76 20.5 104 28.0   
Cancer Stage         4.9  
 Stage 0/I 276 47.1 50 8.5 106 18.1 154 26.3   
 Stage II 321 44.6 59 8.2 137 19.0 203 28.2   
 Stage III 115 46.2 27 10.8 47 18.9 60 24.1   
 Stage IV 52 44.1 12 10.2 18 15.3 36 30.5   
Cancer treatment         36.4 *** 
 Before dep dx 507 44.6 106 9.3 227 20.0 297 26.1   
 After dep dx 194 54.2 17 4.7 41 11.5 106 29.6   






Description of the Study Population by Depression Treatment Categories 
Elderly Fee-for-service Medicare beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-
diagnosed Depression 
SEER-Medicare Database, 2007-2012 
  Antidepressants Psychotherapy Combined No    
  Only  Only  ADs/Psych Treatment   
  N % N % N % N % chisq sig 
Continued, 
Need factors 
Cardiovascular         10.6 * 
 Yes 691 47.0 127 8.6 292 19.9 359 24.4   
 No 73 49.3 21 14.2 16 10.8 38 25.7   
Musculoskeletal         5.7  
 Yes 243 44.8 48 8.8 121 22.3 131 24.1   
 No 521 48.5 100 9.3 187 17.4 266 24.8   
Respiratory         9.5 * 
 Yes 174 45.9 47 12.4 79 20.8 79 20.8   
 No 590 47.7 101 8.2 229 18.5 318 25.7   
ADRD         55.7 *** 
 Yes 83 37.9 33 15.1 71 32.4 32 14.6   
 No 681 46.8 115 7.9 237 16.3 421 29.0   
Anxiety         13.7 ** 
 Yes 205 46.9 25 5.7 99 22.7 108 24.7   
 No 559 45.2 123 10.0 209 16.9 345 27.9   
External Environment 
            
% Psychologists 
(mean (SD))  2.04 (3.92)  3.08 (4.85)  2.81 (4.56) 2.49 (4.23)  *** 
            
Region         59.3 *** 
 Northeast 121 37.5 43 13.3 89 27.6 70 21.7   
 south 243 53.2 24 5.3 60 13.1 130 28.4   
 North-central 92 43.4 23 10.8 49 23.1 48 22.6   
 West 308 45.2 58 8.5 110 16.2 205 30.1   
Cancer diagnosis year        19.4  
 2007-2009 104 39.8 30 11.5 45 17.2 82 31.4   
 2010-2012 178 48.1 36 9.7 61 16.5 95 25.7   
 
Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal or prostate 
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during  
the observation period and Part D during the follow-up period.  Asterisks represent significant differences in study 
population characteristics by depression treatment categories, derived from chi-square statistics. 





AA: African American; ADs: Antidepressants; ADRD: Alzheimer's disease and related disorders; dep: Depression; 
dx: diagnosis; SEER: Surveillance Epidemiology and End Results; Sep/div/wid/unkn: 



















































Table 3.3  
Unadjusted Odds Ratios and 95% Confidence Intervals  of Depression Treatment Categories 
from Multinomial Logistic  Regression on Depression Treatment Categories Elderly Fee-for-service Medicare 
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression 
 SEER-Medicare database, 2007-2012 
 Reference Group = No Depression Treatment 
  Antidepressants Only Psychotherapy only Combined ADs/Psych 
  OR 95%CI Sig OR 95%CI Sig OR 95%CI Sig 
Predisposing factors 
Age in years          
 66-69 1.25 [ 0.89 ,  1.75]  0.93 [ 0.56 ,  1.54]  1.07 [ 0.71 ,  1.60]  
 70-74 1.03 [ 0.74 ,  1.43]  0.74 [ 0.45 ,  1.23]  0.79 [ 0.53 ,  1.19]  
 75-79 0.99 [ 0.70 ,  1.41]  0.58 [ 0.33 ,  1.01]  0.86 [ 0.56 ,  1.31]  
 >=80 (Ref.)          
Race          
 White (Ref.)          
 AA 0.49 [ 0.31 ,  0.77] ** 1.59 [ 0.91 ,  2.78]  1.26 [ 0.79 ,  2.02]  
 Others 0.54 [ 0.36 ,  0.82] ** 0.56 [ 0.27 ,  1.15]  0.41 [ 0.23 ,  0.74] ** 
Enabling factors 
Marital Status           
 Married (Ref.)          
 Never married 1.03 [ 0.65 ,  1.63]  3.11 [ 1.69 ,  5.76] *** 2.15 [ 1.31 ,  3.54] ** 
 Sep/div/wid/Unkn 1.10 [ 0.86 ,  1.42]  1.68 [ 1.10 ,  2.58] * 1.12 [ 0.81 ,  1.54]  
           
Primary care visits 1.00 [ 0.99 ,  1.02]  1.04 [ 1.02 ,  1.05] *** 1.03 [ 1.01 ,  1.05] *** 
Cancer type          
 Breast (Ref.)          
 Women colorectal 0.84 [ 0.62 ,  1.15]  1.30 [ 0.81 ,  2.09]  1.03 [ 0.70 ,  1.51]  
 Men colorectal 0.79 [ 0.52 ,  1.22]  1.66 [ 0.91 ,  3.02]  1.04 [ 0.62 ,  1.76]  
 Prostate 0.87 [ 0.63 ,  1.19]  0.95 [ 0.57 ,  1.59]  1.15 [ 0.79 ,  1.68]  
Cancer Stage          
 Stage 0/I (Ref.)          
 Stage II 0.89 [ 0.68 ,  1.17]  0.90 [ 0.58 ,  1.40]  0.99 [ 0.71 ,  1.39]  
 Stage III 1.03 [ 0.70 ,  1.52]  1.34 [ 0.76 ,  2.36]  1.10 [ 0.69 ,  1.75]  
 Stage IV 0.74 [ 0.46 ,  1.20]  0.95 [ 0.45 ,  1.97]  0.67 [ 0.36 ,  1.25]  
Cancer treatment          
 Before Dep Dx. (Ref.)          
 After Dep Dx. 0.95 [ 0.72 ,  1.26]  0.40 [ 0.23 ,  0.70] ** 0.45 [ 0.30 ,  0.67] *** 
 No Treatment  0.77 [ 0.51 ,  1.17]  1.46 [ 0.85 ,  2.52]  1.09 [ 0.68 ,  1.75]  
Need factors 
Cardiovascular          
 Yes 1.00 [ 0.66 ,  1.51]  0.64 [ 0.36 ,  1.13]  1.93 [ 1.06 ,  3.53] * 
 No (Ref.)          
          
          





Table 3.3  
Unadjusted Odds Ratios and 95% Confidence Intervals  of Depression Treatment Categories 
from Multinomial Logistic  Regression on Depression Treatment Categories Elderly Fee-for-service Medicare 
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression 
 SEER-Medicare database, 2007-2012 
 Reference Group = No Depression Treatment 
  Antidepressants Only Psychotherapy only Combined ADs/Psych 
  OR 95%CI Sig OR 95%CI Sig OR 95%CI Sig 
Musculoskeletal          
 Yes 0.95 [ 0.73 ,  1.23]  0.97 [ 0.65 ,  1.46]  1.31 [ 0.96 ,  1.79]  
 No (Ref.)          
Respiratory          
 Yes 1.19 [ 0.88 ,  1.60]  1.87 [ 1.22 ,  2.86] ** 1.39 [ 0.97 ,  1.98]  
 No (Ref.)          
ADRD          
   Yes  1.39 [ 0.91 ,  2.13]  3.27 [ 1.93 ,  5.56] *** 3.42 [ 2.18 ,  5.35] *** 
   No (Ref.)          
Anxiety          
  Yes 0.98 [ 0.75 ,  1.29]  0.54 [ 0.34 ,  0.88] * 1.27 [ 0.92 ,  1.76]  
  No (Ref.)          
External Environment 
           
% Psychologists 0.99 [ 0.96 ,  1.02]  1.05 [ 1.00 ,  1.11] * 1.05 [ 1.00 ,  1.09] * 
           
Region          
 Northeast 1.08 [ 0.76 ,  1.54]  2.04 [ 1.25 ,  3.32] ** 2.23 [ 1.49 ,  3.32] *** 
 south 1.17 [ 0.88 ,  1.55]  0.61 [ 0.36 ,  1.04]  0.81 [ 0.55 ,  1.19]  
 North-central 1.38 [ 0.91 ,  2.11]  1.84 [ 1.01 ,  3.34] * 2.06 [ 1.27 ,  3.35] ** 
 West (Ref.)          
Cancer diagnosis           
 2007 (Ref.)          
 2008 0.84 [ 0.66 ,  1.07]  0.82 [ 0.56 ,  1.20]  0.99 [ 0.73 ,  1.33]  
 
Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal or prostate 
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during  
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study 
population characteristics by depression treatment categories, derived from multinomial logistic regression. 
 
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 
 
AA: African American; ADRD: Alzheimer's disease and related disorders; CI: Confidence interval; dep: 
Depression; dx: diagnosis; OR: Odds ratio; SEER: Surveillance Epidemiology and End Results; Sep/div/wid/unkn: 





Table 3.4  
Adjusted Odds Ratios and 95% Confidence Intervals  of Depression Treatment Categories 
from Multinomial Logistic  Regression on Depression Treatment Categories Elderly Fee-for-service Medicare 
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression  
SEER-Medicare database, 2007-2012 
Reference Group = No Depression Treatment 
  Antidepressants Only Psychotherapy only  Combined AD/Psych 
  AOR 95%CI Sig AOR 95%CI Sig AOR 95%CI Sig 
Predisposing factors 
Age in years          
 66-69 1.39 [ 0.97 ,  2.01]  1.41 [ 0.80 ,  2.47]  1.52 [ 0.96 ,  2.39]  
 70-74 1.14 [ 0.80 ,  1.62]  1.15 [ 0.66 ,  2.00]  1.07 [ 0.68 ,  1.68]  
 75-79 1.01 [ 0.71 ,  1.45]  0.75 [ 0.42 ,  1.37]  0.96 [ 0.61 ,  1.51]  
 >=80 (Ref.)          
Race          
 White (Ref.)          
 African Americans  0.44 [ 0.27 ,  0.70] *** 1.19 [ 0.64 ,  2.21]  1.02 [ 0.61 ,  1.71]  
 Other races 0.59 [ 0.38 ,  0.92] * 0.49 [ 0.22 ,  1.06]  0.38 [ 0.20 ,  0.71] ** 
Enabling factors 
Marital Status           
 Married (Ref.)          
 Never married 1.14 [ 0.71 ,  1.83]  2.33 [ 1.21 ,  4.48] * 1.68 [ 0.98 ,  2.86]  
 Sep/div/wid/Unkn 1.15 [ 0.87 ,  1.51]  1.57 [ 0.98 ,  2.50]  1.02 [ 0.71 ,  1.45]  
           
PCP visits 1.00 [ 0.99 ,  1.02]  1.02 [ 1.00 ,  1.04] * 1.02 [ 1.00 ,  1.04] * 
           
Cancer types           
 Women Breast  (Ref.)         
 Women Colorectal  0.93 [ 0.67 ,  1.29]  0.97 [ 0.59 ,  1.60]  0.72 [ 0.47 ,  1.09]  
 
Men Colorectal 
Cancer 0.87 [ 0.55 ,  1.35]  1.54 [ 0.81 ,  2.95]  1.04 [ 0.60 ,  1.81]  
 Men Prostate Cancer 1.10 [ 0.76 ,  1.57]  1.01 [ 0.56 ,  1.82]  1.17 [ 0.74 ,  1.85]  
Cancer Stage          
 Stage 0/I (Ref.)          
 Stage II 0.89 [ 0.65 ,  1.22]  0.78 [ 0.47 ,  1.31]  0.83 [ 0.55 ,  1.25]  
 Stage III 1.14 [ 0.76 ,  1.71]  1.11 [ 0.60 ,  2.07]  1.01 [ 0.61 ,  1.69]  
 Stage IV 0.83 [ 0.50 ,  1.37]  0.78 [ 0.36 ,  1.73]  0.66 [ 0.34 ,  1.30]  
Cancer treatment          
 Before dep. Dx (Ref.)          
 After dep dx. 0.95 [ 0.70 ,  1.27]  0.40 [ 0.22 ,  0.72] ** 0.51 [ 0.34 ,  0.79] ** 
 No Treatment  0.83 [ 0.53 ,  1.28]  1.31 [ 0.72 ,  2.40]  0.90 [ 0.54 ,  1.51]  
           
           





Table 3.4  
Adjusted Odds Ratios and 95% Confidence Intervals  of Depression Treatment Categories 
from Multinomial Logistic  Regression on Depression Treatment Categories Elderly Fee-for-service Medicare 
beneficiaries with Breast, Colorectal or Prostate Cancer and Newly-diagnosed Depression  
SEER-Medicare database, 2007-2012 
Reference Group = No Depression Treatment 
  Antidepressants Only Psychotherapy only  Combined AD/Psych 
  AOR 95%CI Sig AOR 95%CI Sig AOR 95%CI Sig 
Need factors 
Cardiovascular          
 Yes 1.04 [ 0.68 ,  1.61]  0.39 [ 0.21 ,  0.74] ** 1.41 [ 0.75 ,  2.68]  
 No (Ref.)          
Musculoskeletal          
 Yes 0.94 [ 0.71 ,  1.24]  0.88 [ 0.57 ,  1.38]  1.15 [ 0.82 ,  1.63]  
 No (Ref.)          
Respiratory          
 Yes 1.22 [ 0.90 ,  1.67]  1.64 [ 1.04 ,  2.58] * 1.20 [ 0.82 ,  1.75]  
 No (Ref.)          
ADRD          
 Yes 1.53 [ 0.98 ,  2.40]  2.58 [ 1.44 ,  4.61] ** 2.94 [ 1.81 ,  4.76] *** 
 No (Ref.)          
Anxiety          
 Yes 0.94 [ 0.71 ,  1.24]  0.48 [ 0.29 ,  0.80] ** 1.17 [ 0.82 ,  1.66]  
 No (Ref.)          
External Environment 
           
% Psychologists 0.99 [ 0.96 ,  1.02]  1.05 [ 1.00 ,  1.11] * 1.05 [ 1.00 ,  1.09] * 
           
Region          
 Northeast 0.99 [ 0.67 ,  1.46]  2.53 [ 1.42 ,  4.52] ** 2.48 [ 1.56 ,  3.95] *** 
 south 1.07 [ 0.77 ,  1.51]  0.74 [ 0.39 ,  1.39]  0.84 [ 0.52 ,  1.34]  
 North-central 1.27 [ 0.81 ,  1.99]  2.27 [ 1.15 ,  4.51] * 2.18 [ 1.26 ,  3.77] ** 
 West (Ref.)          
Cancer diagnosis          
 2007-2009 (Ref.)          
 2010-2012 0.82 [ 0.64 ,  1.05]  0.88 [ 0.59 ,  1.33]  1.02 [ 0.75 ,  1.40]  
 
Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, colorectal or prostate 
cancer and Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during  
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study 
population characteristics by depression treatment categories, derived from multinomial logistic regression. 
 
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 
AOR: adjusted odds ratio; AA: African American; ADRD: Alzheimer's disease and related disorders; CI: 























































Appendix 3.1 Study Cohort Development Flow Diagram for Study Population of Elderly Medicare 







































 Cancer diagnosed identified using Siterwho 1- -10 codes  
          Breast N = 392,684, Colorectal N= 291,491, Prostate N= 461,994 
 Diagnosed with cancer from April 2007 to Dec 2011 
         Breast N = 169,955, Colorectal N= 125,261, Prostate N= 205,505 
 
 Diagnosed with cancer from April 2007 to Dec 2011 
 Primary cancer only in the patient’s lifetime (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases 
Breast N = 129,206, Colorectal N= 89,272, Prostate N= 168,783 
 
Reason for exclusion:  
 Not one primary cancer (n=39,257, 
n=34,683, n=34,738) 
 Diagnosed at autopsy or death cert. 
(n=854, n=1,061, n=1,545) 
 Not incident cases (n=33,418, 
n=30,827, n=32232) 
 
 Elderly with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases, >=66,  alive  
Breast N = 73,496, Colorectal N= 45,571, Prostate N= 107,585 
 
Reasons for exclusion: 
 <66 years old (n=47,290, n=23,744, 
n=56,295) 
 Unknown stage of cancer (n=6,614, 
n=4,619, n=10,185) 
 Death (n=4,063, n=14,434, n=3,822) 
 
Final Analytical Cohort 
 Diagnosed with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”), Not diagnosed with cancer at 
autopsy or death certificate, Incident cases, >=66, alive, Newly-
diagnosed depression. 
 Fee-for-service continuous enrollment A and B 12m before 
depression dxdt and part D 12m after depression dxdt 
Breast N = 752, Colorectal N= 550, Prostate N= 371 
(N = 1,673) 
 
Reasons for exclusion: 
 HMO enrollment and NO Continuous enroll 
in Part A & B (n=443, n=461, n=296) 




 Diagnosed with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”), Not diagnosed with cancer at 
autopsy or death certificate , Incident cases, >=66,   alive  
 Have depression diagnosis 
 Depression free at cancer diagnosis 
 Developed newly-diagnosed  depression at the 12m follow-up 
period 
Breast N = 1,805, Colorectal N= 1,433, Prostate N= 1,050 
Reasons for exclusion: 
 No depression diagnoses (n=65,216, 
n=40,934, n=102,155) 
 Not depression free at cancer diagnosis 
(n=3,810, n=1,774, n=2,340) 
 No developed depression during the 12 









Adjusted Odds Ratios and 95% Confidence Intervals  of Depression Treatment Categories by Cancer Types from 
Multinomial Logistic Regression on  Depression Treatment Categories Elderly Fee-for-service Medicare beneficiaries 
with Breast, Colorectal or Prostate Cancer, SEER-Medicare data from 2007-2012 
  Antidepressants Only Psychotherapy only  Combined ADs/Psych 
  AOR 95%CI Sig AOR 95%CI Sig AOR 95%CI Sig 
Reference Group = Women Breast Cancer 
Cancer types           
 Women Colorectal  Cancer 0.93 [ 0.67 ,  1.29]  0.97 [ 0.59 ,  1.60]  0.72 [ 0.47 ,  1.09]  
 Men Colorectal Cancer 0.87 [ 0.55 ,  1.35]  1.54 [ 0.81 ,  2.95]  1.04 [ 0.60 ,  1.81]  
 Men Prostate Cancer 1.10 [ 0.76 ,  1.57]  1.01 [ 0.56 ,  1.82]  1.17 [ 0.74 ,  1.85]  
 Reference Group = Men Prostate Cancer 
 Women Breast Cancer 0.91 [ 0.64 ,  1.31]  0.99 [ 0.55 ,  1.79]  0.85 [ 0.54 ,  1.35]  
 Women Colorectal Cancer 0.85 [ 0.57 ,  1.28]  0.96 [ 0.51 ,  1.81]  0.61 [ 0.37 ,  1.03]  
 Men Colorectal Cancer 0.79 [ 0.48 ,  1.30]  1.53 [ 0.74 ,  3.18]  0.89 [ 0.48 ,  1.65]  
           
 
Note: Based on 1,673 elderly fee-for-service Medicare beneficiaries with incident breast, Colorectal or prostate cancer and 
Newly-diagnosed depression who were continuously enrolled in Medicare Part A and B during  
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study population 
characteristics by depression treatment categories, derived from multinomial logistic regression. 
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 

















Depression Treatment and Short-term Healthcare Expenditures 
 among Elderly Medicare Beneficiaries with Newly-diagnosed Depression and Incident 





Objectives. Depression is associated with high healthcare expenditures and depression treatment 
may reduce healthcare expenditures. However, to date there have not been any studies on the 
effect of depression treatment on healthcare expenditures among cancer survivors. Therefore, the 
purpose of this study is to examine the association between depression treatment and healthcare 
expenditures among elderly Medicare beneficiaries with newly-diagnosed depression and 
incident breast, colorectal or prostate cancer.  
Methods. The current study utilized a retrospective longitudinal study design using the linked 
Surveillance, Epidemiology and End Results (SEER)-Medicare database. Elderly (> 66 years) 
fee-for-service Medicare beneficiaries with newly diagnosed depression and incident breast, 
colorectal or prostate cancer (N= 1,502) were followed for a period of 12 months after 
depression diagnosis. Healthcare expenditures were measured every month for a period of 12 
months after depression diagnosis. Depression treatment was identified during the six months 
after depression diagnosis and was categorized into four mutually exclusive categories: 1) 
treatment with antidepressants only, 2) treatment with psychotherapy only, 3) combined 
treatment with both antidepressants and psychotherapy and 4) no depression treatment. The 
adjusted associations between depression treatment and healthcare expenditures were analyzed 
with Generalized Linear Mixed Model (GLMM) regressions with gamma distribution and log-





factors. Additionally, the inverse probability weighting technique (IPTW) was used to adjust for 
observed selection bias in depression treatment categories. 
Results. The average 1-year total healthcare expenditures after depression diagnosis were 
$38,219 for those who did not receive depression treatment; $42,090 for those treated with 
antidepressants only; $46,913 for those treated with psychotherapy only and $51,008 for those 
treated with a combination of antidepressants and psychotherapy. As compared to no depression 
treatment, those who received antidepressants had $1,317 higher total healthcare expenditures 
those who received psychotherapy had $2,186 higher total healthcare expenditures; and those 
who received combination of antidepressants and psychotherapy had $2,754 higher total 
healthcare expenditures, after adjusting for selection bias and predisposing, enabling, need, and 
external environment factors. The associations between depression treatment and the higher 
healthcare expenditures were observed across all types of healthcare expenditures. 
Conclusions. Among cancer survivors with newly-diagnosed depression, treatment for 









Depression is highly prevalent among cancer survivors and it has been reported that 
cancer survivors with depression incur higher healthcare expenditures as compared to those 
without depression (1). Among elderly prostate cancer survivors, those with depression had 
33.3% higher healthcare expenditures during the 12 months after cancer diagnosis as compared 
to those without depression (1). Among adults with cancer, those with depression had 31.7% 
higher one-year healthcare expenditures as compared to those without depression (2).   
 While depression leads to increased healthcare expenditures, depression treatment may 
lead to a reduction in healthcare expenditures due to improved health outcomes. However, to 
date there have not been any studies that have examined the association between depression 
treatment and healthcare expenditures in real-world settings. Therefore, this study infer the 
association between depression treatment and healthcare expenditures using findings from 
studies among elderly individuals. These studies have shown mixed results on the association 
between depression treatment and healthcare expenditures. The Improving Mood-Promoting 
Access to Collaborative Treatment (IMPACT) randomized controlled trial (RCT), which 
included 418 individuals aged 60 years or older, found that at the end of 24 months the 
intervention group had $896 lower expenditures as compared to the usual care group (3). Among 
adults with cancer, a RCT found that collaborative care for depression was cost-effective as 
compared to usual care (4,5). However, these trials did not compare the healthcare expenditures 
of those who received depression treatment to those who did not receive any depression 
treatment. A study among elderly fee-for-service Medicare beneficiaries with prevalent 
depression and chronic physical conditions seeking care in real-world practice settings found that 





with/without antidepressants (29%) was associated with an increase in short-term total healthcare 
expenditures (6). A longitudinal study in real-world practice settings found that elderly who 
received antidepressant treatment had 32% higher outpatient expenditures as compared to those 
without antidepressant treatment (Fischer et al., 2002). 
The above-mentioned studies suggest that the relationship between depression treatment 
and healthcare expenditures is not yet established. To the best of our knowledge, there are no 
studies that examine whether depression treatment can reduce healthcare expenditures among 
cancer survivors seeking care in real-world settings. It is important to understand the association 
between depression treatment and healthcare expenditures for many reasons. First, depression is 
associated with poor Health-related Quality of Life (HRQoL), higher healthcare utilization and 
expenditures (1,7), and unplanned readmissions (8-10). Depression treatment can improve health 
outcomes and may reduce healthcare utilization and expenditures. Understanding this association 
is particularly important as a large portion of Medicare healthcare expenditures for cancer 
patients is attributed to the treatment of coexisting health conditions (11). Furthermore, Medicare 
has implemented many payment reforms to ensure high quality care at lower costs (12). Given 
the importance of reducing healthcare spending among Medicare beneficiaries, the current study 
can provide important information on comparative effectiveness of depression treatment to 
payers, policy makers and providers. The primary objective of the current study is to compare 
healthcare expenditures by depression treatment categories among elderly fee-for-service 
Medicare beneficiaries with newly-diagnosed depression and incident breast, colorectal or 







4.3 Conceptual framework 
 
This study utilized the expanded behavioral model on healthcare utilization, the Andersen 
Behavioral Model, to help our selection of the variables that may affect healthcare expenditures 
(13). The model suggests that the utilization of health services varies as a function of 1) an 
individual’s unique predisposition for using services (predisposing factors – age and race); 2) the 
resources available to each individual for obtaining services (enabling factors: cancer type, 
cancer stage, cancer treatment, marital status and Primary Care Physican (PCP) visits), 3) the 
individual’s need  (need factors – depression treatment, the number of chronic physical and 





This study utilized a retrospective longitudinal study design with a 12-month baseline 
(April 2006 through December 2011) and a 12-month follow-up period (April 2007 through 
December 2012).  The baseline period was based on depression diagnosis date and consisted of 
the 12 months before the depression diagnosis date. Healthcare expenditures were measured 
every month for a period of 12 months after depression diagnosis. To capture the variations in 
healthcare expenditures at different time point of follow-up period. This study used the repeated 
measures statistical models. As independent measure design often measure aggregated healthcare 
expenditures at the follow-up period, repeated measures were used because it allowed us to 
capture the expenditures during and after depression treatment.  
Depression treatment was measured during the first six months after depression 
diagnosis. Other explanatory variables were measured during the 12-months before depression 





4.4.2 Data Sources 
The current study linked data from several sources including the SEER-Medicare linked 
database, ACS estimates from census, and the AHRF files. The detailed description of the data 
sources are provided in Chapter 1. 
4.4.3 Study population 
The study population is composed of elderly cancer survivors (age > 66 years) who were 
diagnosed with incident breast, colorectal or prostate cancer and who were newly-diagnosed with 
depression after cancer diagnosis between 2007 and 2011. This study identified the cancer types 
(breast, colorectal or prostate cancer) using the International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3) histology codes and the primary site variable.  
 
Cancer Survivors with newly-diagnosed depression 
This study identified cancer survivors with newly-diagnosed depression based on the 
National Committee on Quality Assurance (NCQA) criteria (15). To achieve this, a depression-
free cancer cohort with incident cancer diagnosis between April 2007 and December 2011 was 
first established. This study used a validated algorithm to identify newly-diagnosed depression 
after cancer diagnosis by including only those who were diagnosed with depression after cancer 
diagnosis and who did not have any antidepressant use 90 days prior to depression diagnosis 
(16). This study used the following codes from the International Classifications of Diseases – 9th 
edition, Clinical Modification (ICD-9-CM): 296.2, 296.3, 298.0, 300.4, 309.1 and 311.0. These 
codes are widely used to identify depression diagnoses in Medicare beneficiaries (1,17,18).  
Inclusion/exclusion criteria  
This study required that all individuals have continuous enrollment in Medicare part A, B 





This study also required that individuals have continuous enrollment in Medicare part D during 
three months prior to and 12 months after depression diagnosis in order to identify depression 
treatment in the follow-up period. This study excluded individuals with unknown cancer stage at 
diagnosis, those diagnosed through autopsy or death certificate, or those who died during the 
follow-up period. Appendix 1.1 summarizes the analytical population selection process. The 
final study population consisted of 1,502 elderly Medicare beneficiaries with newly-diagnosed 
depression and incident breast, colorectal or prostate cancer.  
4.4.4 Dependent Variables  
Type and Total Healthcare Expenditures   
Healthcare expenditures were derived from the Medicare claims files and included the 
amount paid by Medicare. This study identified the type of healthcare expenditure based on 
whether the services were provided in an inpatient, outpatient, prescription drug or home 
healthcare setting. The following types of healthcare expenditures were analyzed; inpatient, 
outpatient, prescription drugs, and other. Other expenditures consisted of DME and HHA 
expenditures. Total healthcare expenditures were derived as the sum of inpatient, outpatient, 
prescription drugs, durable medical equipment and home health agency expenditures.   
 Total and type of healthcare expenditures were classified into yearly and monthly 
expenditures during the follow-up period. Yearly expenditures consisted of expenditures for the 
entire 12-month period after depression diagnosis. Monthly expenditures were calculated for 
every month after depression diagnosis. All healthcare expenditures were adjusted by the 
Consumer Price Index and expressed in 2012 constant dollars. 
4.4.5 Key Independent Variable  
The key independent variable was the depression treatment during the first six months 





the National Drug Codes (NDC) and generic names. Antidepressants included selective serotonin 
reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), tricyclic 
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and others (mirtazapine, 
bupropion). Any cancer survivor with at least one prescription for antidepressants was 
considered to be using antidepressants. Psychotherapy visits were derived from Medicare 
outpatient claims using the Current Procedural Terminology (CPT) codes. 
Based on antidepressant use and psychotherapy visits, depression treatment was 
categorized into four mutually exclusive categories: (1) treatment with antidepressants only: 
individuals received, at least, one prescription of antidepressants and no psychotherapy visits; (2) 
treatment with psychotherapy only: individuals had, at least, one psychotherapy office visit and 
no prescription for antidepressants; (3) both antidepressants and psychotherapy: individuals 
received, at least, one prescription for antidepressants with at least one psychotherapy visit; (4) 
no treatment: individuals received no antidepressants and no psychotherapy. 
4.4.6 Other Independent Variables 
Time-Invariant Variables 
These variables were measured during the baseline period (i.e. 12 months before 
depression diagnosis). Predisposing characteristics included age in years at cancer diagnosis 
(66-69, 70-74, 75-79, >=80) and race (White, African American, and others). Enabling factors, 
included marital status (married, divorced/separated/widowed, and never married), cancer types 
(women with breast cancer, women with colorectal cancer, men with colorectal cancer, men with 
prostate cancer); and stage at cancer diagnosis, categorized using the American Joint Committee 
on Cancer (AJCC) grouped staging (stage 0/I, stage II, and stage III/ IV). Need factors composed 





External environmental characteristics included SEER region (Northeast, South, North-central, 
and West) and the year of cancer diagnosis. 
Time-varying independent variables    
These were measured every month during the follow-up period (i.e. 12-months after 
depression diagnosis) and included PCPs visits and cancer treatment (chemotherapy, radiation 
therapy or surgery).  
4.5 Statistical Analysis 
 
Bivariate Analyses 
T-tests and F-tests were used to examine the unadjusted differences in average healthcare 
expenditures by depression treatment categories. Mean, standard deviation and median were 
used to describe healthcare expenditures by depression treatment categories.  
 Analyses with repeated measures 
As healthcare expenditures were measured for every month during the follow-up period, 
each individual had 12 observations. These 12 observations were not independent, so standard 
regression techniques can not be applied. Therefore, the associations between depression 
treatment and total healthcare expenditures were analyzed with a repeated measures design using 
Generalized Mixed Linear Model (GLMM) regressions with gamma distribution and log link. 
The GLMM model was selected because this study found that 65% of the variation in healthcare 
expenditures was due to differences within individuals. GLMM regressions account for 
correlated error terms due to repeated measures from the same person. In these regressions, 
predisposing, enabling and need factors affecting depression treatment as well as external 





expenditures associated with depression treatment categories, as compared to no depression 
treatment, were calculated.  
Observed Selection Bias: Adjusting for inverse probability weighting technique (IPTW) 
The inverse probability weighting technique (IPTW) was used to adjust for observed 
group differences in depression treatment categories. The IPTW approach calculates weight for 
each individual based on the inverse of their propensity to receive a specific type of depression 
treatment or no treatment. Under this approach, individuals with lower propensity will be up-
weighted and those with higher propensity will be down-weighted. This helps balance the 
probability of treatment across the treatment groups. In order to account for the differences in 
group sizes of the treatment groups, the weights were further stabilized by dividing them with the 
sample size of each treatment group.   
4.6 Results 
 
4.6.1 Characteristics of the study population 
 The study population consisted of 1,502 elderly fee-for-service Medicare beneficiaries 
with incident breast, colorectal or prostate cancer who had newly-diagnosed depression after 
cancer diagnosis. In this study population, 45.0% were women with breast cancer, 22.8% were 
women with colorectal cancer, 10.1% were men with colorectal cancer and 22.1% were men 
with prostate cancer. Also, this study found that 47.4% received antidepressants only, 9.3% 
received psychotherapy only, 18.9% received both antidepressants and psychotherapy and 24.4% 
did not receive any depression treatment. The description of time-invariant and time-varying 






4.6.2 IPTW-adjusted Yearly Healthcare Expenditures by Depression Treatment Categories 
Table 3 summarizes the average 1-year expenditures for depression treatment categories.  
The mean 1-year total healthcare expenditures after depression diagnosis were $38,219 for those 
who did not receive depression treatment, $42,090 for those treated with antidepressants only, 
$46,913 for those treated with psychotherapy only and $51,008 for those treated with a 
combination of antidepressants and psychotherapy. Average 1-year total healthcare expenditures 
were significantly higher for those treated with a combination of antidepressants and 
psychotherapy (p value< 0.001). Also, the average 1-year inpatient and prescription drugs 
healthcare expenditures after depression diagnosis were significantly higher for those treated 
with a combination of antidepressants and psychotherapy (p value< 0.001).  
4.6.3 IPTW-Adjusted Generalized Mixed Linear Models of Monthly Expenditures 
As compared to no depression treatment, depression treatment with antidepressants only 
was associated with a $1,317 increase in total healthcare expenditures, treatment with 
psychotherapy only was associated with a $2,186 increase while treatment with combination of 
antidepressants and psychotherapy was associated with $2,754 increase. As compared to no 
therapy, this study found that treatment with antidepressants only, psychotherapy only, and the 
combination of antidepressants and psychotherapy were associated with high inpatient, 
outpatient and other healthcare expenditures as compared to no therapy (Table 4). 
4.6.4 Sensitivity Analyses   
To ensure robustness of the association between depression treatment categories and 
healthcare expenditures, sensitivity analyses were conducted. These included healthcare 
expenditures without repeated measures (i.e. measuring 1-year healthcare expenditures), mixed 
effect linear models with log-transformed healthcare expenditures (Tables 4 and 5), and 





instrumental variable regression, the percentage of psychologists at the county-level was used as 
an instrument and depression treatment was considered as endogenous. Across all models and 
even after controlling for the unobserved selection bias, depression treatment was associated 
with higher expenditures as compared to no depression treatment. For example, depression 
treatment with psychotherapy only was associated with higher total healthcare expenditures as 
compared to no depression treatment in the GLMM model (Beta: 0.31; SE:0.07), the Mixed 
Linear model with log-transformed expenditures (Beta: 0.40; SE:0.10), the adjusted 1-year 
healthcare expenditures model (Beta: 0.31; SE:0.08) and in the instrumental variable regression 
model (Beta: 0.01; SE:0.01). Depression treatment with antidepressants only was associated with 
higher total healthcare expenditures as compared to no depression treatment in the GLMM 
model  (Beta: 0.20; SE:0.04), the Mixed Linear model with log-transformed expenditures (Beta: 
0.38; SE:0.06), the adjusted 1-year healthcare expenditures model (Beta: 0.13; SE:0.07) and in 
the instrumental variable regression model (Beta: 0.02; SE:0.01). Depression treatment with a 
combination of antidepressants and psychotherapy was associated with higher total healthcare 
expenditures as compared to no depression treatment in the GLMM model (Beta: 0.38; SE:0.05), 
the Mixed Linear model with log-transformed expenditures (Beta: 0.68; SE:0.07), the adjusted 1-
year healthcare expenditures model (Beta: 0.31; SE:0.08) and in the instrumental variable 




 The current study examined the association between depression treatment categories and 
healthcare expenditures among elderly Medicare beneficiaries with newly-diagnosed depression 
and incident breast, colorectal or prostate cancer. To date, the current study is the first one to 





The study findings suggest that depression treatment was associated with an increase in short-
term healthcare expenditures as compared to no depression treatment. Our results are consistent 
with the one published study on depression treatment and expenditures among elderly with 
chronic physical conditions, which found that depression treatment with antidepressants or 
psychotherapy was associated with increase in short-term healthcare expenditures (6). The 
positive association between depression treatment and healthcare expenditures was robust and 
persisted even after adjustment for other factors and across different model specifications.  
The positive association between depression treatment categories and healthcare 
expenditures among cancer survivors has many plausible explanations. There is evidence of 
depression treatment failure in many individuals. For example, the STAR*D (Sequenced 
Treatment Alternatives to Relieve Depression) trial found that only one-third of patients get 
relief for their depressive symptoms with depression treatment (19). Therefore, there may be 
many cancer survivors who did not respond to depression treatment, which may have resulted in 
poor health outcomes and increased healthcare expenditures. However, this study did not 
measure if those who received depression treatment responded to their therapy or not. It is also 
known that adequate depression treatment is critical in improving health outcomes. A study 
among adults found that adherence to antidepressant medication treatment for at least 90 days 
reduced healthcare expenditures (20). However, our study did not measure the adequacy of 
depression treatment or adherence to depression treatment. Therefore, future studies need to 
explore the relationship between adherence to depression treatment and healthcare expenditures 
among cancer survivors.  It is also plausible that under fee-for-service healthcare systems, many 
individuals with both physical and mental health conditions receive fragmented care and such 





 Our findings have significant policy implications. This study estimated the average 
healthcare expenditures over a 12-month period among elderly Medicare with newly-diagnosed 
depression and incident cancer. Therefore, these estimates can be considered as expenditures 
following a new episode of depression in elderly with incident cancer. Such estimates have an 
important implication for Accountable Care Organization’s (ACO’s) Medicare Shared Saving 
Programs for risk adjustment while also setting the expected expenditure benchmark for 
individuals with cancer and newly-diagnosed depression. Also, our study findings have 
implications for the Centers for Medicare and Medicaid Services’s new bundled payment models 
as well as a new payment and delivery model, the Oncology Care Model (OCM), which aims to 
improve the quality of care and care coordination while lowering costs for patients receiving 
chemotherapy. Our findings can help these payment models in building the quality metrics that 
providers must achieve to maximize their payment.  
Further, our study findings also have clinical practice implications. It has been shown that 
collaborative care rather than usual care for depression leads to a reduction in depressive 
symptoms and decreases expenditures (21).  As compared to usual care, the SMaRT Oncology-
2 (Symptom Management Research Trial, Oncology-2) found that integrated collaborative 
treatment for depression among cancer patients was associated with higher remission rates as 
compared to usual care treatment for depression (4,5).  This trial also found that depression 
treatment delivered within a collaborative care model was cost-effective (4,5). Our findings 
suggest that treating depression in the usual care setting may not be sufficient to achieve lower 
costs and collaborative care models may need to become standard clinical practice. In this 
context, it may be important to enroll Medicare beneficiaries with cancer and newly-diagnosed 





including the use of evidence-based treatment of depression, collaboration between health care 
providers and monitoring depression treatment adherence (22,23). 
Our study has many strengths; it is the first that has examined the impact of depression 
treatment on total healthcare expenditures in real-world fee-for-service settings. The use of 
SEER-Medicare data allowed us to use a longitudinal study design and follow patients for a long 
period of time across different providers. Data from Medicare Part D enabled us to identify 
pharmacological therapy for depression and include expenditures related to prescription drugs. 
This study also tested the robustness of the relationship between depression treatment and 
healthcare expenditures using various model specifications. The current study has some 
limitations: the SEER-Medicare data are not developed for research purposes and therefore have 
limitations associated with its use for estimating total healthcare expenditures. This study only 
observed filled antidepressant prescriptions and not antidepressant use. The study findings 
cannot be generalizable to all Medicare beneficiaries because the study population is restricted to 
those residing in SEER regions and to those with fee-for-service Medicare plans. Another 
limitation related to the observational study was the selection bias, although the observable and 
unobservable selection bias were controlled using the inverse probability weighting technique 
and the instrumental variables approach these biases cannot be completely eliminated.  
4.8 Conclusions 
 
 Our study has provided new evidence for the literature on the impact of depression 
treatment on healthcare expenditures among elderly fee-for-service Medicare beneficiaries with 
newly-diagnosed depression and incident cancer seeking care in real-world clinical practice 
settings. This study found that treatment for depression was associated with higher short-term 





different model specifications, even after adjusting for observed and non-observed selection bias. 
Future studies may need to examine whether factors such as adequacy of depression treatment 
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Description of the Study Population by Depression Treatment Categories Elderly Fee-for-service Medicare 
beneficiaries with newly-diagnosed Depression and Incident Breast, colorectal, or Prostate Cancer 
SEER-Medicare Database, 2007-2012 






  N % N % N % N % N % sig  
Total 1,673 100.0 712 47.4 139 9.3 284 18.9 367 24.4  
Predisposing factors 
Age in years            
 66-69 388 25.8 194 50.0 37 9.5 73 18.8 84 21.6  
 70-74 389 25.9 186 47.8 33 8.5 66 17.0 104 26.7  
 75-79 313 20.8 150 47.9 22 7.0 62 19.8 79 25.2  
 >=80 412 27.4 182 44.2 47 11.4 83 20.1 100 24.3  
Race           *** 
 White 1244 82.8 619 49.8 107 8.6 231 18.6 287 23.1  
 AA/others 258 17.2 93 36.0 32 12.4 53 20.5 80 31.0  
Enabling factors 
Marital Status           *** 
 Married  578 38.5 282 48.8 37 6.4 103 17.8 156 27.0  
 Never married 163 10.9 62 38.0 24 14.7 45 27.6 32 19.6  
 Sep/div/wid/Unkn 669 44.5 368 48.4 78 10.2 136 17.9 179 23.5  
Cancer type            
 Breast 676 45.0 338 50.0 55 8.1 122 18.0 161 23.8  
 Women colorectal 343 22.8 155 45.2 37 10.8 66 19.2 85 24.8  
 Men colorectal 151 10.1 67 44.4 20 13.2 27 17.9 37 24.5  
 Prostate 332 22.1 152 45.8 27 8.1 69 20.8 84 25.3  
Cancer Stage            
 Stage 0-I 524 34.9 258 49.2 45 8.6 98 18.7 123 23.5  
 Stage II 649 43.2 299 46.1 58 8.9 128 19.7 164 25.3  
 Stage III/IV 329 21.9 155 47.1 36 10.9 58 17.6 80 24.3  
Need factors 
# Physical Conditions           
 (mean (SD)) 3.05 (1.65) 2.94 (1.59) 3.15 (1.84) 3.43 (1.65) 2.91 (1.66)  
# Mental Conditions            
 (mean (SD)) 7.54 (0.65) 7.59 (0.58) 7.54 (0.71) 7.36 (0.80) 7.58 (0.60)  
External Environment 
Region           *** 
 Northeast 294 19.6 116 39.5 39 13.3 81 27.6 58 19.7  
 south 418 27.8 228 54.5 23 5.5 57 13.6 110 26.3  
             
             






Description of the Study Population by Depression Treatment Categories Elderly Fee-for-service Medicare 
beneficiaries with newly-diagnosed Depression and Incident Breast, colorectal, or Prostate Cancer 
SEER-Medicare Database, 2007-2012 






  N % N % N % N % N % sig  
 North-central 189 12.6 85 45.0 23 12.2 46 24.3 35 18.5  
 West 601 40.0 283 47.1 54 9.0 100 16.6 164 27.3  
Cancer diagnosis year           
 2007-2009 913 60.8 445 48.7 87 9.5 167 18.3 214 23.4  
 2010-2012 589 39.2 267 45.3 52 8.8 117 19.9 153 26.0  
             
 
Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident 
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A and B during  
the observation period and Part D during the follow-up period. Asterisks represent significant differences in study 
population characteristics by depression treatment categories, derived from chi-square statistics. 
 
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 
 
Physical conditions included diabetes, heart disease, hyperlipidemia, hypertension, stroke, arthritis, osteoporosis, 
asthma and chronic obstructive pulmonary disorder. Mental conditions included Alzheimer and other related 
disorders, anxiety, and other mental disorders.  
AA: African American; AD: Antidepressants; Psych: Psychotherapy; SEER: Surveillance Epidemiology and End 




























 Description of Time Varying Independent Variables for the Study Population by Depression Treatment 
Categories Elderly Fee-for-service Medicare beneficiaries  
with Newly-diagnosed Depression and Incident Breast, colorectal, or Prostate Cancer 
 SEER-Medicare Database, 2007-2012 




Treatment   
  N % N % N % N % N % sig  
Total 18,024 100.0 6,476 35.9 677 3.8 660 3.7 10,211 56.7  
Chemotherapy            ** 
 Yes 1,860 10.3 707 38 55 3.0 49 2.6 1,049 56.4  
 No 16,164 89.7 5,769 35.7 622 3.8 611 3.8 9,162 56.7  
Radiation Therapy            
 Yes 947 5.3 357 37.7 28 3.0 32 3.4 530 56.0  
 No 17,077 94.7 6,119 35.8 649 3.8 628 3.7 9,681 56.7  
Surgery             
 Yes 450 2.5 153 34.0 25 5.6 14 3.1 258 57.3  
 No 17,574 97.5 6,323 36.0 652 3.7 646 3.7 9,953 56.6  
             
PCP visits           
 (mean(SD)) 1.49 (0.50) 1.46 (0.50) 1.38 (0.49) 1.36 (0.48) 1.52 (0.50)  
       
 
Note: Based on 12 repeated measures for 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed 
depression and incident breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A and 
B during the observation period and Part D during the follow-up period. Asterisks represent significant differences 
in study population characteristics by depression treatment categories, derived from chi-square statistics. 
 
*** p < .001; **.001 ≤  p  < .01; *.01 ≤ p < .05. 
 
AD: Antidepressants; Psych: Psychotherapy; PCP: Primary Care Provider; SEER: Surveillance Epidemiology and 






















 IPTW adjusted Mean Expenditures by Depression Treatment Categories Elderly  
Fee-for-service Medicare beneficiaries with Newly-diagnosed Depression and Incident Breast, 
colorectal, or Prostate Cancer 
SEER-Medicare database, 2007-2012 
Mean $ (SE) sig Mean $ (SE) sig Mean $ (SE) sig Mean $ (SE) sig 
AD only (N= 712) Psycho only (N= 139) 
Combine AD &  
Psych (N= 284) 
No Depression 
Treatment (N = 367) 
Total Healthcare Expenditures 
42,090 (2,805)  46,913 (4,615)  51,008 (3,530) *** 38,217 (2,227)  
Outpatient Expenditures 
16,812 (1,062)  17,165 (1,748)  15,571 (1,337)  14,815 (844)  
Inpatient Expenditures 
18,039 (2,160)  22,344 (3,554)  27,040 (2,718) *** 18,012 (1,716)  
Prescription Drugs Expenditures 
4,787 (299) *** 3,584 (493)  5,674 (377) *** 3,340 (238)  
Other Expenditures 
2,451 (312)  3,821 (513) *** 2,724 (392)  2,053 (247)  
Among Users of Inpatient and Other Services 
Inpatient Expenditures 
AD only (N= 399) Psycho only (N= 76) 
Combine AD &  
Psych (N= 189) 
No o Depression 
Treatment (N = 202) 
31,692 (3,299)  41,902 (5,561)  40,910 (3,973) * 31,789 (2,623)  
Prescription Drugs Expenditures 
AD only (N= 712) Psycho only (N= 136) 
Combine AD &  
Psych (N= 284) 
No Depression 
Treatment (N = 361) 
4,787 (301) *** 3,660 (498)  5,674 (379) *** 3,389 (240)  
Other Expenditures 
AD only (N= 441) Psycho only (N= 94) 
Combine AD & 
 Psych (N=167) 
No o Depression 
Treatment (N 222) 
3,978 (456)  5,102 (713) * 4,653 (595) * 3,292 (369)  
        
 
Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident 
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A and B and Part D during the 
observation period.  
 
Total healthcare expenditures were the sum of inpatient, outpatient, prescription drug, durable medical equipment, 
and home health agency expenditures. Other expenditures consisted of durable medical equipment and home health 
agency. 
Asterisks indicate statistical significance the average healthcare expenditures by depression treatment categories 
based on T-tests. 
 
***p  <.001; **.001 ≤ p < .01; *.01 ≤ p < .05. 
AD: Antidepressants; Psych: Psychotherapy; N: Number; SEER: Surveillance Epidemiology and End Results; SD: 














 Parameter Estimates of Depression Treatment Categories From GLMM and Mixed Effects linear Model 
On Monthly Healthcare Expenditures, Elderly Fee-for-service Medicare Beneficiaries with Newly-
diagnosed Depression and Incident Breast, Colorectal or Prostate Cancer 
 SEER-Medicare Database, 2007-2012 
Generalized Mixed Linear Model with gamma distribution and log-link  







only (SE) Change# 
AD & 
Psych (SE) Change# 
Total  
8.70*** 

































Prescription Drugs  
5.34*** 
(0.08) 
0.33**   
(0.03) $82 













0.59 **   
(0.18) $224 
0.21    
(0.13) $65 
Mixed Linear Model with Log-transformed Expenditures 





































0.03       
(0.06) 3% 














0.48*   
(0.20) 
0.09       
(0.09) 9% 
0.25        
(0.17) 25% 
0.03    
(0.12) 3% 
        
 
Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident 
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A, B, and D during the 
observation period. Other expenditures consisted of durable medical equipment and home health agency costs. Total 
healthcare expenditures consisted of inpatient, outpatient, prescription drug, durable medical equipment, and home 
health agency expenditures.  
 
# Change was calculated by first exponentiating the intercept term to calculate the expenditures for no depression 
treatment. Then, the sum of the intercept and the parameter estimate for depression treatment type were 
exponentiated to get the expenditures for depression treatment. The differences in these two estimates was reported 
as the change in healthcare expenditures associated with depression treatment. 
% change in expenditures was calculated by exponentiating the parameter estimate and subtracting one (eβ−1).    
 
Models adjusted for time in months, depression treatment, age, race/ethnicity, marital status, PCP visits during each 
month of follow-up, cancer type, cancer treatment during each month of follow-up, cancer stage, and number of 
physical and mental conditions, SEER region, Year of cancer diagnosis.  Asterisks indicate significant differences 
by depression categories as compared to no depression treatment based on GLMM regressions and Mixed linear 
model regressions on healthcare expenditures.  





AD: Antidepressants; IPTW: Inverse Probability Treatment Weights; Psych: Psychotherapy; SE: Standard Error; 








Table 4.5  
Parameter Estimates of Depression Treatment Categories from Generalized Linear Models on One-year 
Healthcare Expenditures Elderly Fee-for-service Medicare beneficiaries with newly-diagnosed Depression 
and Incident Breast, colorectal, or Prostate Cancer 
 SEER-Medicare Database, 2007-2012 
IPTW Adjusted Generalized Linear Model with gamma distribution and Log link 





































0.06    
(0.13) $477 









0.09    
(0.13) $167 





0.21    
(0.13) $188 
0.47*   
(0.21) $478 
0.18    
(0.17) $157 
Unadjusted Generalized Linear Model with gamma distribution and Log link 





































0.06     
(0.13) $262 




















0.20    
(0.17) $188 
        
 
Note: Based on 1,502 elderly fee-for-service Medicare beneficiaries with newly-diagnosed depression and incident 
breast, colorectal or prostate cancer who were continuously enrolled in Medicare Part A, B, and D during the 
observation period. Other expenditures consisted of durable medical equipment and home health agency costs. Total 
healthcare expenditures consisted of inpatient, outpatient, prescription drug, durable medical equipment, and home 
health agency expenditures.  
 
% change in expenditures was calculated by exponentiating the parameter estimate and subtracting one (eβ−1).    
 
Models adjusted for depression treatment, age, race/ethnicity, marital status, PCP visits, cancer type, cancer 
treatment, cancer stage, and number of physical and mental conditions, SEER region, Year of cancer diagnosis.  
Asterisks indicate significant differences by depression categories as compared to no depression treatment based on 
GLM regressions on one-year healthcare expenditures.  
***P <.001; **.001 ≤ P < .01; *.01 ≤ P < .05. 
AD: Antidepressants; IPTW: Inverse Probability Treatment Weights; Psych: Psychotherapy; SE: Standard Error; 





Appendix 4.1 Study Cohort Development Flow Diagram for Study Population of Elderly Medicare 





























 Cancer diagnosed identified using Siterwho 1- -10 codes  
          Breast N = 392,684, Colorectal N= 291,491, Prostate N= 461,994 
 Diagnosed with cancer from April 2007 to Dec 2011 
         Breast N = 169,955, Colorectal N= 125,261, Prostate N= 205,505 
 
 Diagnosed with cancer from April 2007 to Dec 2010 
 Primary cancer only in the patient’s lifetime (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases 
Breast N = 129,206, Colorectal N= 89,272, Prostate N= 168,783 
 
Reason for exclusion:  
 Not one primary cancer (n=39,257, 
n=34,683, n=34,738) 
 Diagnosed at autopsy or death cert. 
(n=854, n=1,061, n=1,545) 
 Not incident cases (n=33,418, 
n=30,827, n=32232) 
 
 Elderly with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”)  
 Not diagnosed with cancer at autopsy or death certificate  
 Incident cases, >=66,  alive  
Breast N = 73,496, Colorectal N= 45,571, Prostate N= 107,585 
 
Reasons for exclusion: 
 <66 years old (n=47,290, n=23,744, 
n=56,295) 
 Unknown stage of cancer (n=6,614, 
n=4,619, n=10,185) 
 Death (n=4,063, n=14,434, n=3,822) 
 
Reasons for exclusion: 
 HMO enrollment and NO Continuous enroll 
in Part A & B 12 months after depression 
diagnosis  (n=399, n=401, n=264) 
 No Continuous enroll in Part D 12 month after 
depression diagnosis (n=210, n=441, n=366) 
 
 
 Diagnosed with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”), Not diagnosed with cancer at 
autopsy or death certificate , Incident cases, >=66,   alive  
 Have depression diagnosis 
 Depression free at cancer diagnosis 
 Developed newly-diagnosed depression from April 2007-Dec 2011 
Breast N = 1,662, Colorectal N= 1,351, Prostate N= 973 
 
Reasons for exclusion: 
 No depression diagnoses (n=65,216, 
n=40,934, n=102,155) 
 Not depression free at cancer diagnosis 
(n=3,810, n=1,774, n=2,340) 
 No developed depression during the 12 
months follow-up period (n=2,665,n=1,430, 
n=2,040) 
 
Final Analytical Cohort 
 Diagnosed with cancer from April 2007 to Dec 2011 
 With primary cancer (Seq1 in “00”), Not diagnosed with cancer at 
autopsy or death certificate, Incident cases, >=66, alive, Newly-
diagnosed depression. 
 Fee-for-service continuous enrollment A and B 12m before 
depression diagnosis and part D 12m after depression diagnosis 
Breast N = 676, Colorectal N= 494, Prostate N= 332 







 SUMMARY AND CONCLUSIONS 
 
5.1 Study Summary and Discussion 
 
This study set out to investigate a new and emerging area of research in the management 
of multiple chronic conditions, specifically the presence and management of depression among 
elderly cancer survivors. While there is a substantial literature on the prevalence of depression 
and its negative impact on health outcomes in cancer, issues related to the incidence and 
treatment of newly-diagnosed depression have received much less attention. Only recently, 
interest has emerged in the ways that treatment of one condition (e.g., depression) influences 
outcomes and costs associated with another condition (e.g., cancer). To date, there have not been 
any studies on variations in the risk of newly-diagnosed depression among cancer types. Also, 
there are no studies on depression treatment and its impact on healthcare expenditures among 
cancer survivors. Our work will be a landmark study in this new generation of research. It will 
point clinicians to opportunities for improved cancer outcomes, and policy-makers to potential 
cost-saving strategies.  
This dissertation focused on answering three related research questions: (1) what is the 
variation in the risk of newly-diagnosed depression by cancer types among elderly cancer 
survivors with incident breast, colorectal or prostate cancer, (2) what are the depression 
treatment rates and what factors affect treatment in cancer survivors and (3) what impact does 
this depression treatment have on healthcare expenditures among cancer survivors? Breast, 
colorectal and prostate cancers were selected as they are the most common types of cancer in 





Although there is evidence that all cancer survivors are at risk for developing depression 
as compared to matched non-cancer cohorts, it is unknown if there are variations in the risk of 
depression between different cancer types. For example, it is possible that some cancer types 
have a higher risk of depression due to poor survival rates or the late stage at which that type of 
cancer is diagnosed. Identifying these variations can help to determine which cancer survivors 
might have a higher risk of depression, thus identifying who can benefit from routine depression 
screening and monitoring to help in early detection and treatment of depression. Therefore, the 
first aim of this study was to evaluate the relationship between cancer types and the risk of 
newly-diagnosed depression with the following comparisons: women with breast cancer were 
compared to women with colorectal cancer while men with prostate cancer were compared to 
men with colorectal cancer.  
  It was observed that elderly women with colorectal cancer had a higher risk of newly-
diagnosed depression as compared to elderly women with breast cancer while elderly men with 
colorectal cancer had a higher risk of newly-diagnosed depression as compared to elderly men 
with prostate cancer. The highest rates of newly-diagnosed depression among colorectal cancer 
survivors, who are typically diagnosed at a later stage, suggest that cancer survival prognosis 
may affect the risk of developing depression.  This study found that cancer survivors with a late-
stage diagnosis were more likely to be diagnosed with depression as compared to those with an 
early-stage diagnosis. This finding suggests that stage at cancer diagnosis can affect the risk of 
developing depression. Further, this study found that cancer survivors who had a higher number 
of primary care visits had a higher rate of newly-diagnosed depression as compared to those with 
fewer primary care visits. Therefore, primary care providers may play an important role in the 





While diagnosing depression is the first step, treating depression with either 
antidepressants, psychotherapy or combined antidepressants and psychotherapy is the next 
critical step to reduce depressive symptoms and improve the clinical outcomes of cancer 
survivors. Even though clinical guidelines recommend depression treatment for cancer survivors 
regardless of cancer types or stage at cancer diagnosis (1,2), elderly cancer survivors may be 
undertreated for depression because cancer is often considered the dominant condition and it 
“eclipses” the management of depression. While there is some research on depression treatment 
rates among cancer survivors with prevalent depression, there are no studies on the rates of 
depression treatment among cancer survivors with newly-diagnosed depression. Therefore, the 
second aim of this study was to estimate depression treatment rates among cancer survivors and 
to examine the factors that affect depression treatment among elderly with newly-diagnosed 
depression and incident breast, colorectal or prostate cancer. 
This study found that nearly 27% of cancer survivors with newly-diagnosed depression 
did not receive any treatment for depression. The majority of the study population received 
antidepressants only to treat newly-diagnosed depression. This study also found that ongoing 
cancer treatment after depression diagnosis was associated with lower rates of depression 
treatment. This finding suggests that the competing demand to treat cancer affects the 
management of depression. Also, individuals with a higher number of primary care provider 
visits were more likely to receive psychotherapy or a combination of antidepressants and 
psychotherapy. This indicates the importance of primary care providers in the management of 
depression. Further, there is evidence that a higher county-level percentage of psychologists was 
associated with a higher use of psychotherapy and a higher use of combination of  





healthcare providers is important in receiving depression treatment. Another finding was that 
there are racial disparities in depression treatment. African American and other racial minorities 
were less likely to receive antidepressant treatment. This suggests that there is a need to reduce 
racial disparities in depression treatment.  
Depression treatment can improve clinical as well as economic outcomes for cancer 
survivors. However, the economic benefits of treating depression have not been evaluated 
previously in cancer survivors. Evidence from real-world clinical practice studies among elderly 
with chronic conditions have suggested that depression treatment for prevalent depression can 
increase short-term healthcare expenditures (5,6). However, the economic benefits of depression 
treatment among cancer survivors with newly-diagnosed depression are yet to be established. 
Therefore, the third aim of this study was to investigate the relationship between depression 
treatment and short-term healthcare expenditures among elderly Medicare beneficiaries with 
newly-diagnosed depression and incident breast, colorectal or prostate cancer.  
The findings indicated that depression treatment during the six months after depression 
diagnosis increased short-term healthcare expenditures. Even after adjustment for observed and 
unobserved selection bias, the positive association between depression treatment and short-term 
healthcare expenditures persisted. This finding was robust using different model specifications.  
 
5.2 Implications of the Findings 
 
5.2.1 Clinical Implications 
The findings from the current dissertation suggests that oncologists and other healthcare 
providers need to provide routine screening for depression especially for individuals who are 
diagnosed with colorectal cancer and those diagnosed at an advanced stage at cancer diagnosis. 





before it becomes severe. In addition, the study findings indicate that detection and treatment of 
depression can be enhanced by visiting primary care providers, suggesting that oncologists can 
play an important role by ensuring that cancer survivors continue visiting their primary care 
providers. 
As competing demands to treat cancer may impede the management of depression, 
oncologists and other healthcare providers may need to recognize that ongoing cancer treatment 
should not delay the management of depression as early depression treatment can improve not 
only depression but also cancer clinical outcomes. However, our study findings suggest that 
receiving depression treatment alone may not be sufficient to improve the economic outcomes of 
cancer survivors in usual care setting. Therefore, integrated coordinated care for depression 
which provides treatment, assessment of response and monitoring adherence to depression 
treatment may be needed to improve depressive symptoms which in turn can improve the 
economic outcomes of cancer survivors. 
 
5.2.2 Policy Implications 
Recognition and treatment of depression are critical cancer care priorities. The findings 
from the current study highlights the need for practice and policy measures to increase the 
screening for depression in cancer survivors with high risk of newly-diagnosed depression. Such 
screening can help in early detection and early management of depression. There is a vital need 
to reduce racial disparities in receiving depression treatment. African-Americans simply do not 
have the same receive antidepressants relative to white Americans, whether due to access to care, 
cultural or economic factors. Further, the management of depression depends very much on the 
availability of psychologists to provide psychotherapy treatment and insufficient supply of 





is a need for policy measures to reduce racial disparities and improve the supply of mental 
healthcare providers.  
The current study suggests that depression treatment is associated with an increase in 
healthcare expenditures. Such findings have implications for the Accountable Health 
Organization (ACOs) Medicare Shared Saving Program expenditures benchmarking and the new 
payment models’ “bundled payment” (3). Under the ACOs, healthcare expenditure estimates can 
be used for risk adjustment while setting the expected expenditures benchmark for individuals 
with cancer and depression who received depression treatment. In addition, it can help the new 
payment models in setting the quality metrics that providers must achieve to maximize their 
payment or for setting the prospective payment for the episode of care provided for cancer 
patients who received depression treatment.  
 
5.3 Unique Contributions of the Study 
 
 This is the first study that has investigated the variations in the risk of newly-diagnosed 
depression among elderly with incident breast, colorectal or prostate cancer and identified cancer 
types with high risk of newly-diagnosed depression. This study’s findings are therefore 
significant since the risk of depression in cancer survivors has, until now, always been compared 
to matched non-cancer cohorts. This study fills this gap. Furthermore, the current study focused 
on depression treatment received after depression diagnosis. Although previous studies have 
estimated depression treatment rates among cancer survivors, all of them have examined 
prevalent depression treatment, which can be before or after depression diagnosis (4,5). This 
study identified many barriers to receive depression treatment which have not been considered in 





Moreover, this dissertation provides a knowledge base on the association between depression 
treatment on short-term healthcare expenditures among cancer survivors. Previous studies among 
cancer survivors focused mainly on how depression increases healthcare expenditures, but none 
of the previous studies investigated whether depression treatment itself can lead to cost savings 
or not.  
5.4 Strengths 
 
 The current study has many strengths related to the data sources used and the study 
design. This study used the most recent available SEER-Medicare data for years 2007 to 2012. 
This data enabled us to use a cohort study design and follow a large number of individuals to 
identify newly-diagnosed depression after cancer diagnosis. Also, the availability of a 
prescription drugs in the SEER-Medicare database enabled us to identify depression treatment 
after depression diagnoses in a real world setting. Further, this study controlled for many 
variables that affect the risk of depression and the treatment of depression, such as cancer stage 
and cancer treatment. Finally, to control for observable and non-observable selection bias this 




  Depression diagnosis may be under-coded in claims data, so this study may have 
underestimated the risk of depression. Additionally, the antidepressants were identified from 
claims, so it is not certain if they were actually used. This study cannot exclude misclassification 
bias; individuals who may have received depression treatment in inpatient and emergency 
department settings and had no claims, were considered as receiving no depression treatment. 





probability weighting technique and the instrumental variable technique were used to control for 
these biases. Further, claims data do not provide information about the severity of depression, 
pain and fatigue, body mass index, attitude, or preferences, which can affect the risk of 
depression and its treatment. The study findings are not generalizable as the study population is 
restricted to those residing in SEER regions, to those with fee-for-service Medicare plans, and to 
those with breast, colorectal and prostate cancer.  
 Despite these limitations, this study provides a knowledge base on the risk of newly 
diagnosed depression after cancer diagnosis, on depression treatment rates and factors affecting 
depression treatment and on the impact of depression treatment on economic outcomes among 
elderly Medicare beneficiaries with incident breast, colorectal or prostate cancer.  
 
5.6 Suggestions for Future Research  
 
 This study identified some unanswered questions that need further investigation in future 
research. As the focus of this study was on the most common types of cancer, future studies may 
need to investigate the risk of newly-diagnosed depression and depression treatment rates among 
elderly with other types of cancer. As the current study found that one-quarter of the individuals 
with depression did not receive any depression treatment, there is a need to explore the reasons 
why so many patients are not receiving therapy and to investigate if these individuals are 
receiving alternative therapy. In addition, as the findings of this study unexpectedly indicated 
that depression treatment increased short-term healthcare expenditures, there is a need to 
investigate whether or not adherence or adequacy of depression treatment can lead to cost 
savings.  Future studies may need to explore the relationship between depression treatment and 
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Appendix A. Codes Related to Cancer Diagnosis and Treatment 
Cancer Diagnosis and Treatment    
 ICD-9-CM Codes 
 Siter-WHO recodes 
ICD-9-CM 
Procedure Codes 
HCPCS/CPT Codes Revenue 
Center 
Codes 
Breast Cancer 26000    
Colorectal Cancer 21041 , 21042, 21043, 
21044, 21045, 21046, 
21047, 21048, 21049, 
21051, 21052 
   
Prostate Cancer 28010    
Cancer Treatment - Surgery    
Breast Cancer  8520-8529, 8533-
8536, 8540-8548 
19120, 19125, 9126, 
19300-19307,  
 
Colorectal Cancer  4530-4534, 4541-
4543, 4549, 4550-
4552,  4561-4563, 
4570-4576, 4579, 
4580-4583, 4590-
4595, 4601, 4603, 






44147, 4150, 44160, 
44204-44208, 4150-




45121, 45123, 5126, 
45395, 45397 
 
Prostate Cancer  602-606 55801, 55810, 5812, 
55815, 5821,55831, 
55840, 55842, 5845, 
55866 
 
Cancer Treatment - Chemotherapy    
 V581, V662, V672 9925, 9928 96401- 96549, Q0083-





Cancer Treatment - Radiation Therapy    
 V580, V661, V671 9220-9239 77261-77799, C1715-
C1720, C2634-C2699, 
C1728 
0330, 0333 
 
 
